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Abstract: MYCN Proto-Oncogene, BHLH Transcription Factor (MYCN) has been one of the most 
studied genes in neuroblastoma. It is known for its oncogenetic mechanisms, as well as its role in 
the prognosis of the disease and it is considered one of the prominent targets for neuroblastoma 
therapy. In the present work, we attempted to review the literature, on the relation between MYCN 
and neuroblastoma from all possible mechanistic sites. We have searched the literature for the role 
of MYCN in neuroblastoma based on the following topics: the references of MYCN in the literature, 
the gene’s anatomy, along with its transcripts, the protein’s anatomy, the epigenetic mechanisms 
regulating MYCN expression and function, as well as MYCN amplification. MYCN plays a signifi-
cant role in neuroblastoma biology. Its functions and properties range from the forming of G-quad-
raplexes, to the interaction with miRNAs, as well as the regulation of gene methylation and histone 
acetylation and deacetylation. Although MYCN is one of the most primary genes studied in neuro-
blastoma, there is still a lot to be learned. Our knowledge on the exact mechanisms of MYCN am-
plification, etiology and potential interventions is still limited. The knowledge on the molecular 
mechanisms of MYCN in neuroblastoma, could have potential prognostic and therapeutic ad-
vantages. 
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1. Introduction 
1.1. A Brief “Ensemble” to MYCN 
MYCN is one of the most studied genes with respect to neuroblastoma. This gene 
was identified back in 1983 by Kohl et al. (1983) [1] and Schwab et al. (1983) [2], which 
was initially found to be amplified in neuroblastoma cases, “homologous to v-myc but 
different from MYC in human neuroblastoma” [3]. Later on, MYCN was found to manifest 
high expression levels, as a result of gene amplification, in neuroblastoma cell lines, met-
astatic neuroblastoma, retinoblastoma and lung tumors [4]. The first report on MYCN (as 
previously was named as myc, n-myc), was by Schwab and Bishop (1988), where they have 
reported that besides its role in human tumors, it participated in various biological pro-
cesses, including senescence [5], resistance to therapy [6] and most interestingly it was 
found that “circular extra-chromosomal DNA molecules could transport amplified 
MYCN proto-oncogenes in human neuroblastomas” [7]. 
MYCN has been extensively studied both in fetal development, as well as for its role 
in human neoplasms. MYCN products are nuclear phosphoproteins with a short half-life. 
It has been shown that in terms of its physiological cellular function, it plays a role in 
neural development of the sympathetic system. Especially, the expression of MYCN 
increases significantly during the fetal stages. It has been shown, in multiple reports, that 
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MYCN overexpression is directly associated with poor prognosis of neuroblastoma and it 
is thought that there is a strong correlation between gene overexpression and the 
evolutionary course of tumors [8]. On the other hand, MYCN has received less attention 
with respect to pediatric brain tumors, while recent reports have highlighted its role in 
the disease [9–11]. Apart from its role in neuroblastoma, MYCN has been studied in some 
extent for other pediatric brain neoplasms such as medulloblastoma [12,13], astrocytoma 
[14], glioblastoma [15,16], and others. One of the main questions in MYCN biology is the 
link between its overexpression and amplification. The gene’s overexpression does not 
always correlate to the gene’s copy numbers and this is a topic under continuing 
investigation. 
The MYCN oncogene is one of the most important genetic biomarkers for the 
diagnosis, prognosis and treatment of neuroblastoma. MYCN overexpression is 
associated with poor prognosis and rapid tumor growth [9,17,18]. However, it does not 
function as a unique f actor rather it is reported to participate in a network of other factors, 
procuring neuroblastoma’s pathology. Examples of other genes linked to MYCN biology 
is the ID2 gene, which is also linked to MYCN overexpression and the fast development 
of the disease as studies have demonstrated the ability of MYCN to act as a transcription 
factor for ID2 [19]. Similar case is the NF2 transcription factor, whose methylation is linked 
to neuroblastoma progression [20]. One significant player in tumor progression, TP73 
tumor suppressor gene, could not be left out of tumor progression. MYCN overexpression 
and TP53 downregulation is considered (and actually very recently) as a twin-target for 
neuroblastoma therapy [21], but also is linked to advanced stages of the disease. 
Beside the aforementioned gene aberrations, chromosomal aberrations are also 
known to play a significant role in neuroblastoma progression. For example, deletion of 
the 1p36 region is also associated with poor disease prognosis, and the region has not yet 
been associated with a tumor suppressor gene [22,23]. Further studies, lead to the 
conclusion that the chromosomal region 1p36 contains some tumor suppressor genes 
which, however, have not yet been detected. Another negative prognostic indicator for 
the poor progression of the disease is the unbalanced enhancement of the chromosomal 
region 17q. The expression of TRKA, TRKB and TRKC receptors (neurotrophic tyrosine 
kinase receptors Types 1, 2, 3) has been associated with a good prognosis of the disease, 
while the gene appears to be suppressed in cases where we have MYCN amplification 
[24]. Other chromosomal aberrations are also known to play a significant role in 
neuroblastoma progression such as 17q and 22p [25]. These chromosomal regions are 
known to code for tumor suppressor genes, which when deleted lead to disease 
progression. 
1.2. The Frequency of MYCN in the Literature 
The search with the keywords “MYCN Neuroblastoma” in PubMed returns 2166 re-
sults until June 12th 2021 (Figure 1). The gene, is one of the most studied genes for a spe-
cific disease. Interest on the MYCN gene and neuroblastoma biology remained constant 
throughout the years. In its almost 40 year history since its first reports, a lot is still to be 
learned on its role in neuroblastoma. The study of MYCN for other types of tumors returns 
much less results, as for example the keywords “MYCN brain tumor” returns 237 hits 
until 12 June 2021. 
  




Figure 1. The literature concerning the role of MYCN in neuroblastoma. A total of 2166 citations come up in the PubMed 
database with the keywords “MYCN” and “neuroblastoma”. 
1.3. A Brief Reference (and History) to Neuroblastoma 
Neuroblastoma was discovered in 1910 by Wright, JH (1910), where in his work he 
referred to the tumor as “neurocytoma” or “neuroblastoma”. In particular, he referred to 
neuroblastoma as “The essential cells of the tumor are considered to be more or less undifferenti-
ated nerve cells or neurocytes or neuroblasts, and hence the names neurocytoma and neuroblas-
toma” [26]. Knowledge on the nature and biology of neuroblastoma increased drastically 
since that time. Prognosis and therapy have greatly improves although in many cases 
neuroblastoma is still fatal. 
Neuroblastomas afford the most common extracranial solid tumors of childhood 
[27]. They commonly occur during the first five years of life and may arise during infancy. 
Potential localizations include the sympathetic nervous system and occasionally the brain, 
but they are also common in the abdomen; most cases arise in either the adrenal medulla 
or the peritoneal sympathetic ganglia. Ganglion cell tumors, neuroblastoma and gan-
glioneuroma, are more common mainly in childhood, but their clinical manifestation 
vary. 
These neoplasms occur most commonly during the first five years of life and may 
arise during infancy. Most neuroblastomas are sporadic, although familial cases occur as 
well. Neuroblastomas may occur anywhere in the sympathetic nervous system and occa-
sionally within the brain, but they are also common in the abdomen; most cases arise in 
either the adrenal medulla or the peritoneal sympathetic ganglia. The adrenal medulla 
derives from the neural crest. It contains two major cell types chromaffin and ganglion 
cells. Chromaffin cells (pheochromocytes) are the predominant medullary cells. They are 
postganglionic sympathetic neurons that have lost their axons and dendrites. They syn-
thesize and release their catecholamines (epinephrine or norepinephrine) in response to 
neural stimulation (especially stress) mediated by preganglionic sympathetic neurons. 
The few parasympathetic ganglion cells present exhibit typical morphological character-
istics of autonomic ganglion cells. 
Under normal circumstances, as aforementioned, chromaffin cells produce two types 
of catecholamines in response to pregaglionic sympathetic stimulation (e.g., stress). Both 
elevate blood glucose by stimulating hepatic glycogenolysis. They also increase blood 
flow to the heart. Epinephrine increases the heart rate and dilates blood vessels to the 
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organs needed to escape stress, such as cardiac and skeletal muscles. It dilates bronchioles 
and constricts the vessels in organs (e.g., skin, digestive tract, kidneys) that are not essen-
tials in reacting to stress. Norepinephrine also constricts blood vessels in non-essential 
organs increasing peripheral resistance and as a result it increases blood pressure and 
blood flow to the heart, brain and skeletal muscles. 
Under abnormal function, hypersecreting chromaffin cell tumors (pheochromocyto-
mas) cause a sustained stress response (especially hypertension) even in the absence of 
stress. While neuroblastoma is a highly malignant tumor of early life (related by matura-
tion to ganglioneuroma), the other principal tumor of the sympathetic nervous system, 
pheochromocytoma, is usually a benign tumor of adults, unrelated to either neuroblas-
toma or ganglioneuroma [28]. Ganglion cell tumors, neuroblastoma and ganglioneuroma, 
are more common, mainly in childhood, but their clinical manifestation vary. 
1.3.1. Clinical Characteristics of Neuroblastoma 
Clinical features are extremely variable and reflect the widespread distribution of 
neural crest tissue. Metastases are common at diagnosis, approximately half of newly di-
agnosed patients have distant metastases, and often cause the symptoms that lead to the 
diagnosis of neuroblastoma. These symptoms are divided into specific and nonspecific. 
Remote effects are occasionally seen. There are three most widely used neuroblastoma 
staging systems: Evans, Pediatric Oncology Group (POG) and TNM- Union Internationale 
Contre le Cancer (UICC) [29]. 
Tumor markers are extremely useful in evaluating children who have neuroblas-
toma. Concerning urinary markers, catecholamines, are elaborated by most tumors are 
useful for diagnosis, follow up on response to therapy, and detection of recurrence. On 
the other hand, serum markers are used, whom elevations are often associated with a poor 
prognosis. Such markers are ferritin and lactate dehydrogenase. Last but not least, MYCN 
represents an oncogene marker whose amplification within the tumor cells is also associ-
ated with poor prognosis [30]. MYCN oncogene is a member of myc family of oncogenes 
that encode transcription factors regulating cell growth. The additional copies of this on-
cogene contribute to the rapid growth of the neuroblastomas that have MYCN amplifica-
tion and thus poor prognosis [31]. Prognosis depends on the following factors: age, stage, 
histopathology (degree of differentiation of tumor cells and their pattern of growth) and 
tumor markers [32]. 
Therapy includes surgery, aggressive multi-agent chemotherapy treatment, espe-
cially if the patient has poor prognostic features such as MYCN amplification and autolo-
gous bone marrow transplantation according to the stage diagnosed. In addition, sponta-
neous regression without any therapy is common in a particular stage [33]. 
1.3.2. Oncogenetic Mechanisms in Neuroblastoma 
Cell cycle is divided in four phases, designated G1, S (when DNA synthesis occurs), 
G2 and M (mitosis, when the cell actually divides). Cells that have ceased dividing (per-
manently or temporarily) are said to be in a resting phase called G0. The ordered progres-
sion from one phase to the next is coordinated by a complex set of proteins, and the cellu-
lar signals that control cell division do so by modulating the activities of those proteins 
which include cyclins, CDKs (cyclin-dependent kinases), CDKIs (CDK inhibitors) [34]. 
Progression through G1, is also marked by the accumulation of other transcription factors, 
which presumably act on other genes required for DNA replication. Several of these fac-
tors are regulated by association with other proteins. 
The ultimate stage of the signal transduction pathway is regulation of DNA tran-
scription in the nucleus. Components of the signal transduction factors that regulate the 
activity of specific genes whose proteins products influence cellular growth and prolifer-
ation. Genes that encode these transcription factors include Myc, Fos and Jun. Mutations 
may occur in any of these steps involved in regulation of cell growth and differentiation. 
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Accumulation of such mutations within a cell lineage may result in progressive deregula-
tion of growth eventually producing a tumor cell. Proto-oncogenes encode products that 
control cell growth and differentiation. When mutated, they may become oncogenes, 
which can cause cancer. Most oncogenes act as dominant gain-of-function mutations that 
lead to deregulation of cell cycle control [35]. In contrast to tumor suppressor genes, most 
oncogenes do not exhibit germline mutations that cause inherited cancer syndromes [36]. 
Instead, somatic mutations are observed that lead to sporadic cancers. 
Retroviruses are a type of RNA virus that is capable of using reverse transcriptase to 
transcribe RNA into DNA. In this way, the RNA genome of the retrovirus is converted to 
DNA, which can be inserted into a chromosome of a host cell. In an earlier cycle of infec-
tion, a retrovirus may have incorporated in a mutant oncogene from the genome of the 
host. When the retrovirus invades a new cell, it can transfer the oncogene in the genome 
of the new host, thus transforming the cell. Transforming retroviruses have also identified 
the nuclear transcription factor genes Myc, Jun and Fos, as other molecular components 
capable of initiating cell transformation. The transcription factor gene associated with 
neuroblastoma is the oncogene MYCN that encodes a DNA-binding protein and is located 
on the 2p24 chromosome [37]. A recent study showed that in neuroblastoma the human 
endogenous retroviruses was abundant, indicating a possible role in the ontogenesis of 
the disease [38]. Interestingly, another recent report has shown that enterovirii responsible 
for other conditions, are implicated in the nerve tissue and possibly in tumorigenesis, in-
cluding neuroblastoma [39]. The role of viral genome in neuroblastoma is still under in-
vestigation and consists of an active research field. 
Myc protein represents a specific example of HLH (helix–loop–helix) proteins which 
consist of short alpha helix connected by a loop to a longer alpha helix. The loop allows 
dimerization of two HLH proteins to occur and form a Y-shaped dimer. Dimerization may 
occur between two of the same proteins (homodimers) or two different proteins (hetero-
dimers) [40]. 
Differences in the level of expression of encoded proteins can, among others, cause 
proto-oncogenes to become oncogenic. In childhood neuroblastoma, the amount of the 
MYCN gene is increased from a diploid number to many dozens per cell. MYCN ampli-
fication is associated with poor prognosis especially in older children than infants and is 
a significant factor in the aggressiveness of the tumor [41]. 
An older DNA microarray analysis suggested there is a link between DNA methyla-
tion and MYCN gene expression, i.e., there is evidence DNA methylation may directly 
control MYCN oncoprotein levels [42]. Epigenetic silencing of potential tumor suppressor 
genes as an alternative mechanism in the absence of genetic mutations has not yet been 
studied systematically in neuroblastomas and needs further investigation. 
In contrast to MYCN gene amplification, the degree of expression of the MYCN gene 
in the tumor does not predict prognosis [43,44], but it has been previously shown that the 
MYCN product (MYCN) is a nuclear phosphoprotein, which can transcriptionally activate 
many genes, either directly (e.g., ID2) or indirectly [45]. In childhood neuroblastoma, the 
amount of the MYCN gene is increased from a diploid number to many dozens per cell. 
MYCN amplification has been associated with poor prognosis especially in older children 
when compared to infants, while it affords a significant factor for tumor aggressiveness 
[41]. 
1.3.3. Prognosis of Neuroblastoma 
Since the advent of MYCN discovery, it is directly linked to the disease’s prognosis. 
Up-to-date, several factors have been added to the criteria for neuroblastoma’s prognosis. 
A recent study highlighted that exportin-T overexpression, is an independent poor prog-
nosis factor in MYCN amplified neuroblastoma [46]. Further on, the most recent neuro-
blastoma risk classification system indicated that the presence of image defined risk fac-
tors (IDRF), MYCN amplification and age are important prognostic factors related to poor 
prognosis [47]. Another prognostic factor recently mentioned was the overexpression of 
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c-myc, which was confirmed to be linked to poor prognosis independently of MYCN am-
plification [48]. Further on, in MYCN non-amplified neuroblastoma, the DST gene was 
linked to good prognosis, with patients overexpressing DST manifesting higher survival 
rates [49]. In cases of metastatic neuroblastoma (those with bone marrow metastasis) ab-
errations in chromosome 10, along with MYCN amplification [22]. Finally, an interesting 
recent study indicated the role of the microenvironment in neuroblastoma prognosis. In 
particular, it has been reported that low expression of IL5 and NKT in the tumor neuro-
blastoma, was linked to poor outcome in MYCN non-amplified tumors [50]. 
1.4. Scope of the Present Work 
In the present work, we review the literature for the significance of MYCN, in neuro-
blastoma. We present old and new knowledge on the prognostic, diagnostic and thera-
peutic properties of MYCN in neuroblastoma. 
2. The MYCN Gene 
The Myc genes consist of a family of regulator genes and proto-oncogenes whose 
products are transcription factors. The Myc family consists of “three related human genes: 
c-myc (MYC), l-myc (MYCL), and n-myc (MYCN)”. MYC was the first gene of this family to 
be discovered. Its name was derived from the v-myc gene, which was the first gene to be 
discovered in this family. The term c-myc, was given due to the homology of c-myc to the 
v-myc gene, which is of viral origin. The v-myc gene is an oncogene present in the avian 
myelocytomatosis virus, as well as a human oncogene upregulated in various tumors. 
Following the discovery of c-myc other members of this family were discovered and 
named n-Myc and l-Myc [51]. 
2.1. The “Anatomy” of MYCN 
The MYCN, is constructed by 6455 nucleotides and is located on Chromosome 2 with 
exact location 2p24.3 and has three exons (Figure 2). It can be accessed through the gene 
ID 4613 (https://www.ncbi.nlm.nih.gov/gene/4613, accessed 18 June 2021) in the NCBI, 
Gene database with official name is “MYCN proto-oncogene, bHLH transcription factor”. 
The complete anatomy of the gene is presented in Figure 3A and Table 1. The gene has 
twelve TATA-Box sites, which are located between nucleotides 3930 and 6382 (Figure 3B 
and Table 2). 
 
Figure 2. The location of MYCN on Chromosome 2. 
  





Figure 3. The analysis of the MYCN gene with its complete anatomy (A) and the TATA boxes (B) 
(ORF: open reading frame, TFBS: transcription factor binding site, CDS: gene coding region). 
Table 1. The analysis of the MYCN gene (table has been reproduced from the NCBI provided data 
https://www.ncbi.nlm.nih.gov/gene/4613, accessed 20 June 2021.). 
Type Start Stop Strand Comment 
source 1 6455 5′→3′ 
/gene = MYCN 
/gene_synonym = MYCN-AS1; N-CYM; NCYM; NYCM 
/organism = Homo sapiens 
/mol_type = genomic DNA 
/db_xref = taxon:9606 
/chromosome = 2 
gene <1C 1884 3′→5′ 
/note = MYCN opposite strand; Derived by automated  computational analysis 
/db_xref = GeneID:10408 
/db_xref = HGNC:HGNC:16911 







/ncRNA_class = lncRNA 
/product = MYCN opposite strand, transcript variant 1 







/ncRNA_class = lncRNA 
/gene = MYCNOS 
/gene_synonym = MYCN-AS1; N-CYM; NCYM; NYCM 
/product = MYCN opposite strand, transcript variant 3 







/ncRNA_class = lncRNA 
/gene = MYCNOS 
/gene_synonym = MYCN-AS1; N-CYM; NCYM; NYCM 
/product = MYCN opposite strand, transcript variant 2 









/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/product = MYCN proto-oncogene, bHLH transcription factor, transcript variant 1 
/transcript_id = NM_001293228.2 












/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/product = MYCN proto-oncogene, bHLH transcription factor, transcript variant 2 
/transcript_id = NM_005378.6 









/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/product = MYCN proto-oncogene, bHLH transcription factor, transcript variant 2 







/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/product = MYCN proto-oncogene, bHLH transcription factor, transcript variant 3 







/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = isoform 2 is encoded by transcript variant 3; 
/codon_start = 1 
/product = N-myc proto-oncogene protein isoform 2 
/protein_id = NP_001280160.1 













/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = isoform 3 is encoded by transcript variant 2; 
/codon_start = 1 
/product = N-myc proto-oncogene protein isoform 3 
/protein_id = NP_001280162.1 
/db_xref = GeneID:4613 
/db_xref = HGNC:HGNC:7559 










/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = isoform 1 is encoded by transcript variant 2; 
/codon_start = 1 
/product = N-myc proto-oncogene protein isoform 1 
/protein_id = NP_005369.2 
/db_xref = CCDS:CCDS1687.1 
/db_xref = Ensembl:ENSP00000281043.3 
/db_xref = GeneID:4613 
/db_xref = HGNC:HGNC:7559 

















1570 1656 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 




1696 1782 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = propagated from UniProtKB/Swiss-Prot (P04198.2); Region: Interaction with 
AURKA and FBXW7./evidence=ECO:0000269|PubMed:27837025 
misc_fea-
ture 
2296 2298 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = Phosphoserine, by CK2./evidence=ECO:0000269|PubMed:1425701; propagated 
from UniProtKB/Swiss-Prot (P04198.2); phosphorylation site 
misc_fea-
ture 
2302 2304 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = Phosphoserine, by CK2./evidence=ECO:0000269|PubMed:1425701; propagated 
from UniProtKB/Swiss-Prot (P04198.2); phosphorylation site 
misc_fea-
ture 
5450 5515 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 







/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = isoform 1 is encoded by transcript variant 1; 
/codon_start = 1 
/product = N-myc proto-oncogene protein isoform 1 
/protein_id = NP_001280157.1 













1570 1656 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 




1696 1782 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = propagated from UniProtKB/Swiss-Prot (P04198.2); Region: Interaction with 
AURKA and FBXW7./evidence=ECO:0000269|PubMed:27837025 
misc_fea-
ture 
2296 2298 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = Phosphoserine, by CK2./evidence=ECO:0000269|PubMed:1425701; propagated 
from UniProtKB/Swiss-Prot (P04198.2); phosphorylation site 
misc_fea-
ture 
2302 2304 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = Phosphoserine, by CK2./evidence=ECO:0000269|PubMed:1425701; propagated 
from UniProtKB/Swiss-Prot (P04198.2); phosphorylation site 





5450 5515 5′→3′ 
/gene = MYCN 
/gene_synonym = bHLHe37; MODED; N-myc; NMYC; ODED 
/note = propagated from UniProtKB/Swiss-Prot (P04198.2); Region: Leucine-zipper 
Table 2. TATA-Boxes on the MYCN gene. 
Inv. Location (5′→3′) Subsequence Pattern 
1 3930 TATA-box TATAAAA 
2 4401 TATA-box ATATATA 
3 4402 TATA-box TATATAT 
4 4403 TATA-box ATATATA 
5 4882 TATA-box ATATATA 
6 4883 TATA-box TATATAT 
7 6271 TATA-box TATATAT 
8 6272 TATA-box ATATATA 
9 6273 TATA-box TATATAT 
10 6274 TATA-box ATATATA 
11 6275 TATA-box TATATAT 
12 6382 TATA-box TATATAT 
2.1.1. Transcription Factor Binding Sites 
Gene regulation is further controlled by transcription factors, on the so-called tran-
scription factor binding sites (TFBS). TFBS can be predicted either experimentally or bio-
informatically. In the present work we have attempted to identify possible TFBS on the 
MYCN gene using the Webgestalt (http://www.webgestalt.org/, accessed 20 June 2021) 
web-based tool [52–55]. Hence, predicted TFBS were the NF1, E2F, AP4 and FREAC2. 
Further on, two regions on the gene’s product were identified as potential interacting sites 
with AURKA and FBXW7 [56], and one site was predicted to be a Leucine-zipper region. 
2.1.2. Gene Ontology (GO) Annotation 
The gene ontology annotation for the gene reports as functions: “enables DNA bind-
ing” [57], “enables DNA-binding transcription activator activity” [58], “RNA polymerase 
II-specific” [59], “enables DNA-binding transcription factor activity” [60], “enables DNA-
binding transcription factor activity, RNA polymerase II-specific” [60], “enables RNA pol-
ymerase II cis-regulatory region sequence-specific DNA binding” [58], “enables kinase 
binding” [56], “enables protein binding” [56,57,61–69] and “enables protein dimerization 
activity” [70]. In addition, the gene’s biological processes are: “involved in branching mor-
phogenesis of an epithelial tube”, “involved in cartilage condensation”, “involved in em-
bryonic digit morphogenesis”, “involved in embryonic skeletal system morphogenesis”, 
“involved in lung development”, “involved in negative regulation of astrocyte differenti-
ation”, “involved in negative regulation of gene expression” [71], “involved in negative 
regulation of reactive oxygen species metabolic process”, “involved in positive regulation 
of cell death”, “involved in positive regulation of gene expression” [72], “involved in pos-
itive regulation of mesenchymal cell proliferation”, “involved in positive regulation of 
production of miRNAs involved in gene silencing by miRNA” [71], “involved in positive 
regulation of transcription by RNA polymerase II” [58], “involved in positive regulation 
of transcription, DNA-templated” [73], “involved in regulation of inner ear auditory re-
ceptor cell differentiation”, “involved in regulation of transcription by RNA polymerase 
II” [60] and “involved in regulation of transcription by RNA polymerase II” [59]. 
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2.1.3. G-Quadraplexes in MYCN 
G-quadraplexes were first discovered in the early 1960s, where four-stranded DNA 
structures were discovered in nucleotide sequences rich in guanines [74]. G-quadruplex 
are tertiary DNA structures, which are formed in nucleic acid polymers that are rich in 
guanine [75] (Figure 4). G-quadraplexes can take different shapes, where each one con-
tains “guanine-tetrads”, forming single- [76], double- [77], and quadruple-strands [78]. G-
quadraplexes usually form in the telomeric regions, yet they form on oncogene sites [79]. 
The mechanism through which such a quadruplex forms is known to be through the 
Hoogsteen hydrogen bonding, creating a square planar or also known as “guanine-tet-
rad”. When multiple tetrads assemble or “stack” form the G-quadraplex. There are several 
variations of G-quadraplexes. These different forms can be divided into the intramolecu-
lar and intermolecular complexes. The intramolecular complexes are further divided to 
the parallel, anti-parallel, hybrid and higher order complexes, while the intermolecular 
complexes are further divided to bimolecular, trimolecular and tetramolecular structures 
[80]. The quadraplex is stabilized by the presence of a cation, which in most cases is po-
tassium, yet other cations can also participate in quadruplex stabilization. G-quadraplexes 
can be predicted computationally and even experimentally through crystallization stud-
ies. 
Similarly, several studies (but not many) have investigated the presence of G-quad-
raplexes in the MYCN gene. We have also investigated the possibility of the presence of 
G-quadraplexes on the MYCN gene, using the QGRS Mapper [81]. In Figure 5 we provide 
an overview of the possible sites, where G-quadraplexes can form based on the nucleotide 
sequence as well as in Figure 6, we have designed a map of G-Quadraplexes on the gene 
itself. Interestingly, further studies have discovered the 3D structure of MYCN G-quad-
raplexes. One recent study, has reported on the potential G-quadraplex structures of 
MYCN (Figure 7), where they have investigated the nucleotide sequences 5′- T-A-G-G-G-
C-G-G-G-A-G-G-G-A-G-G-G-A-A-3′ (Figure 7A,B) as well as the nucleotide sequence 5′- 
T-A-G-G-G-C-G-G-G-A-G-G-G-A-G-G-G-A-A-T-A-G-G-G-C-G-G-G-A-G-G-G-A-G-G-G-
A-A-3′ (Figure 7C,D). 
 
Figure 4. G-Quadraplex. A tetrad forms with the addition of an ion (left), while multiple tetrads 
form the quadraplex (https://en.wikipedia.org/wiki/G-quadruplex#cite_note-ReferenceC-4, ac-
cessed 20 June 2021). 
  




Figure 5. The predicted G-quadraplex sequences on the MYCN nucleotide sequence (image ob-
tained from the QGRS Mapper web-tool, https://bioinformatics.ramapo.edu/QGRS/index.php, ac-
cessed 21 June 2021. Map was reconstructed using the gene ID 4613 from the NCBI site). 
 
Figure 6. The reconstructed MYCN map based on the previous predictions from Figure 5 (legend: G4: G-Quadraplex po-
sition). 
  




Figure 7. A 3D reconstruction of MYCN G-Quadraplexes. The transversal (A) and lateral (B) views of the 5′- T-A-G-G-G-
C-G-G-G-A-G-G-G-A-G-G-G-A-A-3′nucleotide sequence’s G-quadraplex are presented as depicted from the deposited 
structure 2LEE (https://www.rcsb.org/structure/2LEE, accessed 21 June 2021) in the Protein Data Bank (PDB) database 
(https://www.rcsb.org/, accessed 21 June 2021) [82]. Similarly, The transversal (C) and lateral (D) views of the 5′- T-A-G-
G-G-C-G-G-G-A-G-G-G-A-G-G-G-A-A-T-A-G-G-G-C-G-G-G-A-G-G-G-A-G-G-G-A-A-3′ nucleotide sequence’s G-quad-
raplex are presented as depicted from the deposited structure 2LED (https://www.rcsb.org/structure/2LED, accessed 21 
June 2021) in the PDB [82] (available structures have been reproduced with the Accelrys Discovery Studio software v.2.5). 
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The presence of G-quadraplexes in the MYCN gene, plays a functional role, where it 
has been shown that they are very stable at the promoter site, regulating the gene’s ex-
pression [83]. The importance of MYCN G-quadraplexes, with respect to its prognostic, 
diagnostic and therapeutic use is still under investigation. However, some studies have 
highlighted that chemotherapeutics are able to recognize G-quadraplexes as for example, 
the alkaloids tetrandrine and isotetrandrine were able to bind to MYCN G-quadraplex 
[84]. From the same study, it was shown that tetrandrine had a “high possibility of binding 
to the MYCN G-quadraplexes” through hydrogen bonding, while isotetrandrine did not 
manifest the same affinity. However, it appeared that G-quadraplexes could be possible 
attractive sites for tumor therapy [84]. Similarly, another study showed that Enniatin B, 
“a well-known antibacterial, antihelmintic, antifungal, herbicidal, and insecticidal com-
pound” [85], manifested high binding affinity to MYCN G-quadraplex implying possible 
therapeutic effects [86]. 
2.2. The “Anatomy” of MYCN’s Transcripts 
The MYCN gene transcribes to four known transcripts namely the MYCN proto-on-
cogene, bHLH transcription factor (MYCN), Transcript Variant 1, mRNA 
(NM_001293228.2, accessed 20 June 2021), the MYCN proto-oncogene, bHLH transcrip-
tion factor (MYCN), Transcript Variant 3, mRNA (NM_001293231.2, accessed 20 June 
2021), the MYCN proto-oncogene, bHLH transcription factor (MYCN), Transcript Variant 
2, mRNA (NM_001293233.2, accessed 20 June 2021) and the MYCN proto-oncogene, 
bHLH transcription factor (MYCN), Transcript Variant 2, mRNA (NM_005378.6, accessed 
20 June 2021). 
2.2.1. MYCN Proto-Oncogene, bHLH Transcription Factor (MYCN), Transcript Variant 
1, mRNA 
The NM001293228 mRNA, is a 2923 nucleotide long transcript. It consists of three 
exons, where the first ranges from Nucleotide 1 to 504, the second from Nucleotide 505 to 
1411 and the third from Nucleotide 1412 to 2923. The gene coding region is from Nucleo-
tide 622 to 2016. We have also calculated the secondary structure of the transcript, which 
is shown in Figure 8. There is not known how the secondary structure of this transcript 
participated in neuroblastoma progression and ontogenesis. 
 
Figure 8. The predicted secondary structure of the MYCN, NM001293228 transcript. In particular, the tree structure (A) 
and the dot structure (B) of the transcript are presented (predictions were performed with the Matlab® (The Mathworks, 
Inc., Natick, MA, USA), using the RNAfold method). 
In addition, we have calculated the 3D structure of the first exon of this specific tran-
script (Nucleotides 1–504). The reason, why we have tested the first 500 nucleotides, was 
due to the fact that it is computationally very challenging to create 3D predictions of large 
molecules. Just for reference, the secondary structure prediction of the ~3000 long nucleo-
tide, needed approximately 15 h of computation in i7 8-core computer with 24GB memory 
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capacity and two 1GB CUDA graphics cards. This points out, not only the difficulty of 
calculating and predicting the 3D structures of RNAs, but also, and even more, the pre-
diction of their functional properties. Out of pure curiosity, we wanted to examine and 
visualize how a 3D mRNA would look, and in addition, if we could find something about 
its functional properties (Figure 9). There are no known properties for the functional role 
of the 3D MYCN’s RNA structure, which makes it an interesting topic for future research. 
 
Figure 9. The predicted 3D structure of the MYCN, NM001293228 transcript and in particular, of the 
first exon (Nucleotides 1–504) (3D structure was predicted using the RNAcomposer web-tool [87,88] 
and it was then visualized using the Accelrys Discovery Studio). 
2.2.2. MYCN Proto-Oncogene, bHLH Transcription Factor (MYCN), Transcript Variant 
3, mRNA 
The NM001293231 mRNA, is a 1706 nucleotide long transcript. It consists of two ex-
ons, where the first ranges from Nucleotides 1 to 194 and the second from Nucleotides 
195 to 1706, while the gene coding region is from Nucleotide 38 to 799. Similarly, we have 
also calculated the secondary structure of the transcript, which is shown in Figure 10. As 
in the case of NM001293228, there are no known relations of the secondary structure of 
this transcript to neuroblastoma progression and ontogenesis or to other molecular func-
tions. Since this transcript was smaller, we were able to model the 3D structures of exon 1 
(Figure 11A) as well as part of the CDS region of the transcript (Figure 11B). Similarly to 
the NM001293228 transcript, the prediction of the secondary structure required around 
10 h with the same hardware configuration as aforementioned. There are no known prop-
erties for the functional role of the 3D MYCN’s RNA structure, which makes it an inter-
esting topic for future research. 




Figure 10. The predicted secondary structure of the MYCN, NM001293231 transcript. In particular, the tree structure (A) 
and the dot structure (B) of the transcript are presented (predictions were performed with the Matlab® (The Mathworks, 
Inc. Natick, MA, USA), using the RNAfold method). 
 
Figure 11. The predicted 3D structure of the MYCN, NM001293231 transcript and in particular, of the first exon (Nucleo-
tides 1–194) (A) and the CDS (Coding DNA Sequence) sequence (nucleotides 38-518) (B) (3D structure was predicted using 
the RNAcomposer web-tool [87,88] and it was then visualized using the Accelrys Discovery Studio). 
2.2.3. MYCN Proto-Oncogene, bHLH Transcription Factor (MYCN), Transcript Variant 
2, mRNA 
The NM001293233 mRNA, is a 2613 nucleotide long transcript. It consists of three 
exons, where the first ranges from Nucleotide 1 to 194, the second from Nucleotide 195 to 
1101 and the third from Nucleotide 1102 to 2613. The gene coding region is from nucleo-
tide 38 to 376. Similarly, we have also calculated the secondary structure of the transcript, 
which is shown in Figure 12. As in the case of the previous transcripts, there are no known 
relations of the secondary structure of this transcript to neuroblastoma progression and 
ontogenesis or to other molecular functions. In the case of this transcript the CDS region 
is 339 nucleotides long and we were able to predict the complete 3D structure of it (Figure 
13). There are no known properties for the functional role of the 3D MYCN’s RNA struc-
ture, which makes it an interesting topic for future research. In addition, this variant lacks 
the Segment 1b in the 5′ region, compared to Variant 1 [89]. This variant has two ORFs, 
the MYCNOT, which is translated from the upstream ORF. The MYCNOT has been found 
to be a long non-coding RNA embedded within the MYCN gene [90]. Further on, this 
variant (along with the following NM005378 variant) are suspected to participate in the 
G-Quadraplex structures, formed by the MYCN gene, and thus probably regulating its 
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functions in cell physiology. A recent report has highlighted that this transcript variant 
probably is responsible for the MYCN mRNA expression levels, as in several cases MYCN 
amplification, is not correlated to high mRNA levels [91]. However, up-to-date its func-
tion is still not well-defined, but there is a hint of its role in anti-apoptosis, which is in 
agreement to the overall role of MYCN in neuroblastoma. 
 
Figure 12. The predicted secondary structure of the MYCN, NM001293233 transcript. In particular, the tree structure (A) 
and the dot structure (B) of the transcript are presented (predictions were performed with the Matlab® (The Mathworks, 
Inc. Natick, MA, USA), using the RNAfold method). 
 
Figure 13. The predicted 3D structure of the MYCN, NM001293233 CDS region (nucleotides 38–376). The proximal (A) 
and the distal (B) lateral views are presented (3D structure was predicted using the RNAcomposer web-tool [87,88] and it 
was then visualized using the Accelrys Discovery Studio). 
2.2.4. MYCN Proto-Oncogene, bHLH Transcription Factor (MYCN), Transcript Variant 
2, mRNA 
The NM005378 mRNA, is a 2613 nucleotide long transcript. It is similar to the 
NM001293233 transcript and consists of three exons, where the first ranges from Nucleo-
tide 1 to 194, the second from nucleotide 195 to 1101 and the third from Nucleotide 1102 
to 2613. The gene coding region is from nucleotide 312 to 1706. As in the case of the 
NM001293233 transcript, this also lacks segment 1b in the 5′ region. It includes two ORFs, 
where the one variant is translated from the downstream ORF, encoding the same isoform 
1. The function of this transcript is unknown, and it is still under investigation. Overall, 
the transcription regulation of MYCN is considered a very complex phenomenon, since 
the MYCN transcripts have a very short half-life, making them difficult to study [92]. 
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2.3. The “Anatomy” of MYCN’s Protein 
The MYCN product (MYCN) is a nuclear phosphoprotein, which can activate tran-
scriptionally many genes, either directly (e.g., ID2) or indirectly [45]. A recent DNA mi-
croarray analysis suggested there is a link between DNA methylation and MYCN gene 
expression i.e., there is evidence DNA methylation may directly control MYCN oncopro-
tein levels [42]. Epigenetic silencing of potential tumor suppressor genes as an alternative 
mechanism in the absence of genetic mutations has not yet been studied systematically in 
neuroblastomas and needs further investigation. 
Each of the aforementioned transcripts is registered to provide variants of the MYCN 
protein. In particular, the NM001293228 produces the NP_001280157.1 N-myc proto-on-
cogene protein isoform 1, the NM001293231 transcript produces the NP_001280160.1 N-
myc proto-oncogene Protein Isoform 2, the NM001293233 transcript produces the 
NP_001280162.1 N-myc proto-oncogene Protein Isoform 3 and the NM005378 transcript 
produces the NP_005369.2 N-myc proto-oncogene Protein Isoform 1. There is one refer-
ence to the solved structure of the MYCN protein (Figure 14) [73]. This is a member of the 
MYC family and encodes a protein with a basic helix–loop–helix (bHLH) domain. This 
protein is located in the nucleus and must dimerize with another bHLH protein in order 
to bind DNA. Multiple alternatively spliced transcript variants encoding different 
isoforms have been found for this gene. The NP001280157 variant represents the full-
length transcript. “Its Exon 1 includes Segments 1a and 1b (also known as Exon 1a and 
Exon 1b) encoding Isoform 1” (Provided by https://www.ncbi.nlm.nih.gov/pro-
tein/NP_001280157.1, accessed 5 July 2021) [89]. The NP001280160 variant (transcript var-
iant 3) “lacks Segment 1b and Exon 2, which results in an upstream AUG start codon, as 
compared to Variant 1. The resulting isoform (Isoform 2) has a shorter and distinct N-
terminus, compared to Isoform 1” (provided by https://www.ncbi.nlm.nih.gov/pro-
tein/NP_001280160.1, accessed 5 July 2021). On the other hand, the NP001280162 variant 
(Transcript Variant 2) lacks Segment 1b in the 5′ region, compared to Variant 1. “This var-
iant includes two open reading frames; the isoform (3, also known as MYCNOT [89]) rep-
resented by NM001293233is translated from the upstream open reading frame. The Iso-
form 3 has an identical N-terminus to that of the Isoform 2, and the function of the Isoform 
3 is currently unknown” (provided by https://www.ncbi.nlm.nih.gov/pro-
tein/NP_001280162.1, accessed 5 July 2021). Finally, the NP005369 isoform is derived from 
the Transcript Variant 2 and lacks Segment 1b in the 5′ region, compared to Variant 1. 
“This variant includes two open reading frames; Isoform 1 represented by the NM005378 
transcript, is translated from the downstream open reading frame. This transcript and 
Variant 1 encode the same Isoform 1” (provided by https://www.ncbi.nlm.nih.gov/pro-
tein/NP_005369.2, accessed 5 July 2021). 




Figure 14. The predicted 3D structure of the MYCN protein with UniProt accession Nr. P04198 [73] 
(protein was visualized with Accelrys Discovery Studio). 
2.4. The Cellular Functions of MYCN 
One of the first discovered functions of MYCN, was its role in cell cycle regulation. 
As the cell cycle is a tightly regulated process, MYCN has been found to play a significant 
role in its regulation. It has been reported that MYCN amplification is linked to the failure 
of cells to arrest in the G1 phase [93]. This is facilitated by the inhibition of PI3K, which 
downregulates MYCN protein levels, lowering proliferation and leading to a reduction in 
S- and M phase cells [94]. Along with PI3K regulation, reduced MYCN expression is cor-
related to other cell cycle regulators such as the CDK inhibitor p27, E2 factor (E2F) and 
inhibitor of differentiation 2 (ID2). P27 is known to be upregulated in case of MYCN inhi-
bition, which in turn reduces CDK levels and thus G1-arrest inhibition [95]. Thus, MYCN 
amplification is directly linked to the aberrant enhancement of cell cycle. 
Further on, MYCN has been found to play a “dual role” in the regulation of apoptosis 
[96]. Recent reports have indicated that MYCN is implicated in the upregulation of the 
“pro-apoptotic regulator phorbol-12-myristate-13-acetate-induced protein 1” (NOXA). 
MYCN does not induce apoptosis directly, yet it sensitizes the cell to be more responsive 
to cytotoxic agents [97]. Therefore, it is known that MYCN inactivation, leads to tumor 
regression through proliferation arrest and the induction of apoptosis [96]. Interestingly, 
MYCN is involved in the control of chromatic acetylation levels in the cell, which has been 
exploited as a therapeutic target since the HDAC inhibitor suberoylanilide hydroxamic 
acid (SAHA), significantly reduced MYCN levels in MYCN-amplified cells, leading to in-
duction of apoptosis [98]. 
As the regulation of cell cycle and apoptosis, were expected to be the “theatrical 
stage” for MYCN, metabolism is the prime highlight. As cancer cells require large 
amounts of energy, they rely to glycolysis for their energy resources, yet another way of 
surviving comes from glutamine catabolism [99]. Tumors with amplified MYCN have 
been shown to manifest increased glutamine transport and glutamate metabolism. This 
has been exploited as a potential therapeutic intervention, where glutamine deprivation 
in neuroblastoma led to increased cell death [100]. 
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The role of MYCN in cellular physiology is well-studied and there are numerous re-
ports concerning this topic. Yet, it becomes apparent that there is still much to be learned 
fort its biology. 
3. Detection of the MYCN Gene 
Neuroblastoma tumors show remarkable biological heterogeneity. Therefore, to pre-
dict the biological behavior of an individual tumor several parameters have been pro-
posed to predict the prognosis of neuroblastoma patients. These include DNA ploidy and 
deletion of the short arm of Chromosome 1, MYCN gene amplification and TrkA expres-
sion and telomerase activity [101]. The use of molecular analysis as a prognostic factor 
relies on the simplicity, reliability and the rapidity of the chosen procedure. The detection 
of gene amplification can be carried out using the fluorescence in situ hybridization (FISH) 
[102] and Southern Blotting (SB) techniques, both of which require a significant amount 
of high quality DNA and several days in order to obtain the results. Sometimes, the sam-
ples obtained by aspiration or biopsy, are small and other times archival paraffin embed-
ded tissue may be used, making it difficult to obtain enough quantity/quality of DNA. In 
cases where the assay is required in order to determine the appropriate therapeutic regi-
men the above techniques are unsuitable since they are not rapid. 
One of the popular methods used is the polymerase chain reaction (PCR) and the 
reverse transcription PCR (RT-PCR). These are powerful procedures for the amplification 
of small amounts of DNA or mRNA respectively, for molecular analysis. These proce-
dures are efficient since they require only small amounts of sample, they are rapid and in 
the case of PCR even partially degraded DNA can be used. The downside of these tech-
niques is the fact that in both cases the results are qualitative. Therefore, the exact gene 
copy number of MYCN cannot be evaluated with the PCR technique. However, the use 
of this innovative technology, gives the advantage of examining a large number of sam-
ples and quantifying the gene and its expression. In Figure 15, we present an example of 
Real-Time PCR, from unpublished in-house experimentation with the Kelly cell line. This 
cell line was an ideal model for MYCN amplification, since it is reported to have a ×100 
MYCN amplification [2,4,5]. 
 
Figure 15. An example of real-time PCR with the Kelly cell line from in-house unpublished data. 
4. Molecular Mechanistics of the MYCN Gene 
Neuroblastoma is presented at diagnosis with extreme heterogeneity. This is 
probably to the fact that neuroblastoma is inherently a complex and heterogeneous tumor 
from a biological and genetic perspective. A series of genomic lesions have been 
discovered in neuroblastoma, each depending on the methodological advancements in 
the course of time. Initially, the first observations concerned the aberrant number of 
chromosomes, followed by chromosomal aberrations, such as deletions, translocations, 
fusions and amplifications. Further on, advances in gene expression came to add more 
information to the knowledge on neuroblastoma’s biology. This kind of knowledge, 
initially concerning pure research findings, was added to the diagnostic and prognostic 
tools for the tumor, as well as to the treatment algorithms of neuroblastoma. 
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4.1. Other Molecular Biomarkers Besides MYCN 
Ploidy is characteristic of all tumors. In the case of neuroblastoma, tumors are 
separated into two main categories; the semi-diploid (45% of tumors) and quasi-triploid 
tumors (55% of tumors). Ploidy has a prognostic significance in patients younger than two 
years of age. It has been reported that triploid tumors are usually presented with loss of 
whole chromosomes, whereas diploid or almost-diploid tumors manifest a major 
impairment of genome stability leading to chromosomal rearrangements, such as 
unbalanced permutations. In general, it is reported that triploid tumors have a better 
prognosis [103,104]. 
Aside from MYCN aberrations, there are several other chromosomal abnormalities 
present in neuroblastoma. A much known chromosomal aberration is the 1p deletion, 
which is often associated with MYCN amplification, but it is also frequent without it. It 
affects the 1p36 region and it is found in the 23–35% of all neuroblastic tumor cases. It is 
associated with patient’s unfavorable prognosis, where in some cases it remains an 
independent prognostic indicator, especially in localized, non-metastatic tumors. It is 
possible that neuroblastoma tumor suppressor oncogenes are located in the 1p36 region 
and their deletion favors oncogenesis. Such genes include the CHD5 and KIF1B genes, as 
previously reported [105–108]. 
Another chromosomal aberration includes the 11q deletion and in particular deletion 
of the 11q23 region. This type of chromosomal aberration, is found in the 26–44% of 
neuroblatoma patients and is inversely related to MYCN amplification. This finding 
divides neuroblastoma patients to two large categories; those with MYCN amplification 
and those with 11q23, indicating that these two aberrations are mutually exclusive. This 
aberration, is known to have prognostic value, especially for low- and intermediate-risk 
neuroblastoma. In this region, the CADM1 gene is located, another tumor suppressor 
gene, whose deletion is probably linked to neuroblastoma progression [106,107,109,110]. 
Similarly to the previous deletions, neuroblastoma manifests a deletion in the 3p 
region, which is known to co-exist with the 11q23 deletion. Both deletions are known, up-
to-date, to be present without a MYCN amplification or a 1p36 deletion. In addition, this 
deletion is more frequent in patients of older diagnostic age, indicating that it is probable 
a distant event in the process of oncogenesis. Similarly to the aforementioned aberrations, 
this region hosts the RASSF1A gene, whose methylation is also known to be linked to 
tumor progression [107]. 
A frequent chromosomal aberration of neuroblastoma is the duplication of the 17q 
region. It occurs in the 80% of all neuroblastoma cases and is often the result of unbalanced 
shifts on chromosomes 1p or 11q. Genes located in that region include the NME1, NME2 
and PPM1D genes (91). In the previous aberrations, it was hypothesized that tumor 
progression was caused due to the deletions of tumor suppressor genes, while in the 
present case tumor progression is probably connected to the amplification of oncogenes. 
Gene mutations in neuroblastoma have been largely studied and the candidate genes 
are countless. However, an interesting case is presented with the mutations of the ALK 
gene. These mutations are found to be present in 15% of all sporadic neuroblastoma cases. 
The ALKF1174L mutation has been shown to enhance the oncogenic activity of the 
amplified MYCN oncogene. The ALK gene codes for a tyrosine kinase and is found not 
only in neuroblastoma but also in lung malignancies and lymphomas. Mutations of the 
ALK gene and the signal transduction pathways involving it, probably induce oncogenesis 
and are thought as possible therapeutic targets [111–118]. In addition to MYCN mutations 
analysis in neuroblastoma, gene expression studies have been used in order to classify the 
tumor. For example, the expression footprint of six neuroblastoma-related genes (ALK, 
BIRC5, CCND1, MYCN, NTRK1 and PHOX2B) have been used to differentiate 
neuroblastoma molecular subtypes [119]. 
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4.2. Epigenetic Regulation of the MYCN Gene 
Besides the aforementioned chromosomal aberrations, much is known on the epigenetic 
regulation of MYCN in neuroblastoma. Epigenetic regulation of MYCN, includes its interaction 
with miRNA, as well as the methylation status of the gene. It is known that MYCN is targeted by 
miRNAs, suppressing MYCN protein expression [107,117,120]. In this section we will deal with the 
current knowledge on the interactions between MYCN and miRNAs, as well as its epigenetic 
regulation through methylation. 
4.2.1. MYCN and miRNAs 
MiRNAs are small single-stranded non-coding RNA molecules (of about 22 nucleo-
tide long) found in all organisms and function as RNA silencing molecules, regulating 
gene expression post-transcriptionally [121]. MiRNAs bind to their RNA-targets via the 
nucleotide complementarity principle [122]. The result from the interaction between miR-
NAs and mRNAs is the silencing of the second, through three main processes; The first 
concerns mRNA cleavage, the second concerns the destabilization of the mRNA through 
shortening of its poly(A) tail, and finally the third concerns the inhibition of translation in 
the ribosomes [123]. Similarly, the MYCN gene is known to be regulated by miRNAs [124]. 
A search for possible miRNA targets of MYCN revealed a total of 234 miRNAs, using the 
miRDB database [125–128], which we present in the Supplementary Materials Table S1. 
Since the MYCN gene is known to be amplified in neuroblastoma it is expected that most 
miRNAs, would be negative regulators of the gene. We have searched each miRNA sep-
arately for its known roles in neuroblastoma and with respect to MYCN. The details of the 
predicted miRNAs were searched with the miRBase web-tool [129–134]. 
The majority of miRNAs are reported to be down-regulated in neuroblastoma and in 
particular, they are found to directly suppress MYCN expression (Table 3). Therefore, in 
all neuroblastoma cases those miRNAs were found to be down-regulated. Some interest-
ing observations were remarked for several miRNAs, which were found to be up-regu-
lated in neuroblastoma and with a direct link to MYCN. In particular, the miR-17~92 clus-
ter, which includes the miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1 
members [135] (Table 3). Those miRNAs, are reported to be up-regulated in neuroblas-
toma and in particular their over-expression is facilitated by MYCN. It is possible that 
those miRNAs are enhanced by the gene by an indirect mechanism that attempts to pro-
mote tumor progression. 
Table 3. MYCN-related miRNAs. Out of 234 miRNAs targeting MYCN, twenty were studied for their role in neuroblas-
toma. 
miRNA Symbol Accession Relation between miRNA and MYCN 
miRNA Expression in 
Neuroblastoma 
Effect on Therapy-Re-




















MIR34A directly suppresses 
MYCN 
Down-regulated 
Induces chemo- and 
radiosensitivity 
Cole et al. (2008) 
[138] 
Di Paolo et al. 
(2020) [139] 
Soni et al. (2013) 
[140] 
Stallings et al. 
(2009) [141] 





MIR202 directly suppresses 
MYCN 
Down-regulated Unknown 
Li et al. (2014) 
[143] 






MIR335 directly suppresses 
MYCN 
Down-regulated Unknown 





MIR144 directly suppresses 
MYCN 
Down-regulated 
Induces chemo- and 
radiosensitivity 





MIR107 directly suppresses 
MYCN 
Down-regulated 
Induces apoptosis, cell 
cycle arrest, chemosen-
sitivity 








Gan et al. (2016) 
[147] 
hsa-miR-7 MIR7 MI0000127 
MIR7 probably enhances 
MYCN indirectly 
Up-regulated Unknown 





MIR29A directly suppresses 
MYCN 
Down-regulated Unknown 





MIR29B directly suppresses 
MYCN 
Down-regulated Unknown 





MIR98 directly suppresses 
MYCN 
Down-regulated Unknown 





MIR145 directly suppresses 
MYCN 
Down-regulated Unknown 




MIR19A MI0000073 MYCN enhances MIR19A Up-regulated 
Represses neuronal 
differentiation 





MIR19B directly suppresses 
MYCN 
Down-regulated Unknown 
Kumps et al. 
(2013) [72] 


















Induces apoptosis, cell 
cycle arrest 




MIR106A MI0000113 MYCN enhances MIR106A Up-regulated 
Promotes cell prolifer-
ation 




MIR20A MI0000076 MYCN enhances MIR20A Up-regulated 
Promotes cell prolifer-
ation 




MIR17 MI0000071 MYCN enhances MIR17 Up-regulated 
Promotes cell prolifer-
ation 
Claeys et al. (2019) 
[156] 
Samaraweera et al. 
(2017) [155] 
Naraparaju et al. 
(2016) [157] 
Buechner et al. 
(2011) [158] 
Loven et al. (2010) 
[152] 
Schulte et al. 
(2008) [154] 
4.2.2. MYCN Methylation and Methylation-Related Mechanisms 
Gene methylation is known to play an extremely important role in all parts of cellular 
and tissue physiology. Similarly, several studies have been conducted for the role of meth-
ylation in neuroblastoma and MYCN. Up to date, there are not much data on the methyl-
ation status of MYCN in neuroblastoma. Yet, there are several reports concerning the role 
of methylation of other genes in neuroblastoma, in both tumors with amplified MYCN or 
not. One of the main findings on neuroblastoma is that the tumor is characterized by the 
extensive methylation of many tumor suppressor genes [159]. This is the case in almost 
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all neuroblastoma cases irrespectively of MYCN amplification. Interestingly, a recent re-
port has highlighted that miRNAs also have been found methylated in neuroblastoma cell 
lines, hinting towards their role in tumor progression [160]. Some of these miRNAs in-
cluded LET7G, MIR124-2, MIR1490, MIR15599, MIR23B, MIR24-1, MIR27B, MIR34C, 
MIR34B2 and MIR196A-1 [160] (Table 4). In almost all cases gene promoter methylation 
was mainly related to tumor progression and poor prognosis (Table 4). We have found 
two exceptions to this rule. The first concerned the NR4A3 gene and actually the Nr4a3 
gene in a mouse model (Table 4). A recent study has highlighted that cells with MYCN 
amplification were found to have a hypo-methylation pattern of the NR4A3 gene’s Exon 
3, while those tumors with a methylated Exon 3, manifested potentially better prognosis 
[161]. In addition, three different studies indicated another exception, concerning the 
CD44 gene (Table 4). In both MYCN amplified and non-amplified neuroblastoma, CD44 
was found to play a dual role that is when un-methylated was manifesting high expres-
sion levels, redirecting to tumor suppression, while when hyper-methylated it was related 
to tumor progression [162–164]. 
Table 4. MYCN-related methylation in neuroblastoma. 
















Korschunov et al. 
(2021) [165] 
Schmitt-Hoffner 


















Lin et al. (2020) 
[168] 





ylation confers tumor sensi-
tivity 
Gupta et al. 
(2018) [169] 








ylation confers tumor sensi-
tivity 
Westerlund et al. 
(2017) [159] 





ylation confers tumor sensi-
tivity 
Wong et al. (2017) 
[170] 
LET7G, MIR124-2, MIR1490, 
MIR15599, MIR23B, MIR24-1, 
MIR27B, 






ylation confers tumor sensi-
tivity 
Parodi et al. 
(2016) [160] 




Liu et al. (2016) 
[171] 
PCDHB, ABCB1, CACNA1G, 









ylation confers tumor sensi-
tivity 
Henrich et al. 
(2016) [172] 





ylation confers tumor sensi-
tivity 








Fabian et al. 
(2016) [173] 





ylation confers tumor sensi-
tivity 
Ikram et al. (2016) 
[174] 










Sun et al. (2015) 
[175] 
NNAT, TP73, CCND, RUNX32, 
CTSZ, DUSP2, HPN, JAK2, 
LRRC4, MAGEA2, MGMT, 








Yanez et al. (2015) 
[176] 
Gonzalez-Gomez 








Dreidax et al. 
(2014) [178] 




Haruta et al. 
(2014) [179] 
Lazcoz et al. 
(2007) [180] 















Uekusa et al. 
(2014) [161] 




Asada et al. 
(2013) [162] 
Lazcoz et al. 
(2007) [180] 
Fulda et al. (2006) 
[182] 
Casciano et al. 
(2004) [183] 
Gonzalez-Gomez 

















Casala et al. 
(2013) [185] 
KRT19, FAS, PRPH, CNR1, 






Decock et al. 
(2012) [186] 




Decock et al. 
(2012) [186] 




Unknown (found in older 
patients) 
Lau et al. (2012) 
[187] 







Lau et al. (2012) 
[187] 







Lau et al. (2012) 
[187] 
Gonzalez-Gomez 




Both Unknown Unknown Unknown 
Sugito et al. 
(2013) [188] 




Djos et al. (2012) 
[189] 
Misawa et al. 
(2009) [190] 
Michalowski et 
al. (2008) [20] 
Lazcoz et al. 
(2007) [180] 
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al. (2012) [191] 
CD44, RASSF1A, CASP8, PTEN, 





Hoebeeck et al. 
(2009) [163] 




Nair et al. (2007) 
[192] 




Lazcoz et al. 
(2007) [193] 
CD44 expressing 














Yan et al. (2003) 
[164] 
4.2.3. Other Epigenetic and Post-Translational Mechanisms in Neuroblastoma 
Up to date there are not many studies concerning the role of other epigenetic (e.g., 
acetylation) or post-translational mechanisms in neuroblastoma. The existent studies have 
investigated this phenomenon through the application of inhibitors and by observing the 
outcome. For example, a recent study has found that the inhibitor SF1126, which inhibits 
BRD4 bromodomain binding to acetylated lysine residues with histone H3 as well as PI3K 
activity in a MYCN amplified neuroblastoma cell line, manifested tumor inhibitory effects 
and was proposed as a potential therapeutic agent [194]. 
In another interesting study, it has been proposed that a known anti-depressant, 
fluoxetine, was able to induce apoptosis in neuroblastoma cells. Interestingly, fluoxetine 
was able to induce apoptosis through two mechanistic pathways; the caspase cascade and 
the probably the hyper-acetylation of histone H3 and H4, upregulation of p300 histone 
acetyltransferase (HAT), as well as the downregulation of histone deacetylases (HDAC) 
[195]. However, this was observed in MYCN amplified cells, while it was not apparent in 
MYCN non-amplified or MYCN knock-down cells [195]. The results from this study, in-
dicated that MYCN is actively participating in other post-transcriptional and post-trans-
lational modifications. The case of fluoxetine, is of great interest since it is a substance that 
is used for the treatment of different conditions. In the same context, another recent work 
indicated the use of anti-diabetic drugs, such as metformin and phenformin, in the treat-
ment of neuroblastoma. The treatment of neuroblastoma cells, both with or without 
MYCN amplification, with metformin and phenformin resulted to increased apoptosis 
rates and inhibition of cell proliferation. One the possible mechanisms through which 
these drugs act is the augmentation of H3 acetylation [196]. 
Another study, indicated that the drug romidepsin, a selective histone deacetylase 
inhibitor (HDAC1/2), was able to induce apoptosis to neuroblastoma cells. In this study, 
it appeared that neuroblastoma progression is probably linked to the extensive histone 
acetylation and its inhibition was able to destabilize tumor progression [197]. Further on, 
it has been reported that MYCN and HDAC genes are functioning in cooperation in neu-
roblastoma. At the same time another gene the Grainyhead-like 1 (GRHL1), which is 
known to be critical in Drosophila neural development, was found to be one of the main 
targets of HDAC inhibitor treatment in neuroblastoma [198]. It was found that an increase 
in the histone H4 “pan-acetylation” in association with its promoter was followed by ex-
tensive transcriptional activation [198]. The HDAC3 and MYCN genes are physically co-
localized to the GRHL1 promoter and they are probably able to repress its transcription. 
In cases of high GRHL1 expression, in neuroblastoma, tumor progression was sup-
pressed, as well as patient survival was more favorable. Thus, it appeared that neuroblas-
toma with or without MYCN amplification, manifested low proliferation rates and sensi-
tivity to therapy if GRHL1 was present [198]. 
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4.3. MYCN Gene Amplification: “The Oldest Trick in the Book” 
MYCN is known to regulate the proliferation, growth, differentiation and survival of 
cells of the developing nervous system [199]. Initial karyotyping techniques, has shown 
that large chromosomal abnormalities are found in the 1p region of Chromosome 1. This 
finding became known in the mid-1980s, where it was found that this chromosomal 
aberration was linked to ectopic MYCN amplification, which is located on the short arm 
of chromosome 2p24 [200]. It became apparent that the presence of MYCN amplification 
affected patients with advanced neuroblastoma and manifested an unfavorable 
prognosis. Numerous studies have shown that MYCN overexpression leads to the 
development of neuroblastic tumors and it seems that this is achieved by regulating p53 
levels, regulating key mechanisms of cell apoptosis [201]. In general, although MYCN 
controls a large number of genes, only a small number of regulatory genes have been 
studied. Interestingly, the high expression of MYCN-controlled genes is not only 
characteristic of MYCN-amplified tumors but is also found in other high-risk neuroblastic 
tumors that do not show MYCN amplification. However, in addition to MYCN, several 
other cytogenetic abnormalities have been frequently observed in neuroblastic tumors. 
Most involve the loss of genomic material. 
MYCN amplification, drives one out of six cases of neuroblastoma. The mechanisms 
through which amplification takes place are still obscure, yet a recent report indicated that 
gene amplification is related to a sort of “enhancer high jacking” of the MYCN gene [202]. 
In particular, they have reported that there are two mechanistic approaches for the gene’s 
amplification. The first includes the co-amplification of the proximal enhancer driven by 
the noradrenergic core regulatory circuit (CRC), while the second involves the ectopic 
“enhancer hijacking”, contributing to the loss of local gene regulatory elements [202]. 
A number of genetic characteristics of neuroblastic tumors have significant 
prognostic value. These include tumor ploidy, MYCN amplification, and for tumors 
without MYCN amplification the type of chromosomal lesions that emerge. Tumors with 
poly-ploidy have a better prognosis as compared to tumors that are diploid. This is 
especially true for patients without MYCN amplification and of younger age (less than 18 
months of age) [203]. On the other hand, triploid tumors are known to have the best 
prognosis, while tetraploid tumors have a prognosis similar to diploid tumors (inferior) 
[104]. The most important and most known aberration of neuroblastoma, with an 
unfavorable prognosis, is MYCN amplification. 
One of the first discoveries concerning the molecular mechanistic of neuroblastoma, 
concerned the discovery of MYCN amplification. Thirty years ago it was realized that an 
increase in the MYCN copy-number is associated with rapid tumor progression in 
neuroblastoma [31]. Following that discovery, MYCN amplification emerged and it was 
discovered its relation to the unfavorable outcome of neuroblastoma [203–205]. In the 
meantime, MYCN amplification became a “standard operating procedure” in terms of 
neuroblastoma diagnostics, as well as its categorization [206]. MYCN amplification can be 
detected at any stage of the tumor’s progression, although it is particularly rare in Stage 1 
tumors. 
The frequency of MYCN amplification has been found to be at 25% of all 
neuroblastomas and in 40% of high-risk neuroblastomas [96,201]. The definition for 
MYCN amplification requires the detection of at least four copies more as compared to the 
normal alleles. Frequently, MYCN amplification is found in neuroblastoma cell lines, 
which ranges from 20 to 40 times [200]. From a mechanistic point of view, it has been 
reported that MYCN activity is probably related to NM23-H1 and NM23-H2 genes located 
in the 17q region [207]. In addition, MYCN expression has been reported to be linked to 
activation by the TP53 gene and thus regulating the escape from apoptosis of neuroblastic 
cells [201]. Another important molecular event thought to participate in MYCN 
amplification is the presence of ALK mutations in neuroblastoma [112]. Interestingly, 
along with MYCN amplification, ALK has also been reported to be amplified in 
neuroblastoma [208,209]. In addition, it has been found that in tumors without MYCN 
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amplification a number of other chromosomal aberrations are present. Such examples 
include the gain or deletion of complete chromosomes such as gain of Chromosome 17, 
Chromosome 7, Chromosome 2 and deletions of Chromosomes 3, 4, and 14 [210]. 
Similarly, it is possible to observe the gain or deletion of chromosomal regions, such as 
the loss of Location 1p of Chromosome 1, 11q on Chromosome 11, 14q on Chromosome 
14 and 3p in Chromosome 3. Similarly, most frequent chromosomal gains are the 17q and 
2p [210]. The latter, is also known to be present with ALK amplification. The deletion of 
specific chromosomal regions is known to be present in neuroblastoma progression due 
to the concurrent deletion of tumor suppressor genes that is these specific regions are the 
loci of tumor suppressors and their absence favors tumor progression. Such examples are 
the 1p, 3p and 11q regions. Similarly, the gain of chromosomal regions is tightly related 
to the amplification of oncogenes, favoring tumor ontogenesis [211–213]. An older report 
has indicated that the presence of complete chromosomal loss or gain was related to more 
favorable outcome, as compared to the loss or gain of specific chromosomal regions 
[214,215]. 
4.4. Therapeutic Interventions with MYCN 
One of the first interventions in the treatment of neuroblastoma is chemotherapy, but 
of equal value comes surgical intervention and removal. Surgery is not always the first 
choice, as neuroblastoma manifests a diffuse character during its growth, making surgery 
impossible. Yet, there are several factors that can modify the decision for surgical inter-
vention. All recent reports agree on the fact that disease staging is crucial for the treatment 
of the disease [47,216]. It has been reported that surgical treatment and its success is linked 
to the image defined risk factors (IDRF), which include the crossing and extending of the 
tumor, the engulfment of vessels, the compression of other organs and the encasing of 
nerves [217]. It would be interesting to find molecular factors that could lead to the deci-
sion for surgical intervention, yet to the best of our knowledge, none exist up-to-date. 
Since the discovery of MYCN amplification in neuroblastoma, it became apparent 
that MYCN could pose an attractive therapeutic target. The first report including MYCN 
as potential target came by Lu et al. (2003) [218]. In the time course of research, it became 
evident that simultaneous inhibition of multiple targets could prove useful in the treat-
ment of neuroblastoma. For example, a recent study has reported that the simultaneous 
inhibition of MYCN and mTOR using bromodomain extra-terminal protein inhibitors and 
temsirolimus manifested significant cell survival suppression [219]. Another study 
showed that the use of PARP and CHK1 inhibitors synergized to induce death in neuro-
blastoma cells and in primary cultures of MYCN amplified and MYCN overexpressing 
cells [220]. In agreement with our previous comments for the role of MYCN in cellular 
metabolism, a recent study highlighted this approach as a possible therapeutic interven-
tion. In particular, they have reported that the pyrimidine biosynthetic enzyme dihy-
droorotate dehydrogenase (DHODH) consisted of a potent therapeutic target for MYCN-
amplified neuroblastoma. Thus, they have shown that inhibition of DHODH suppressed 
the proliferation of MYCN-amplified neuroblastoma cells [221]. Up-to-date there are nu-
merous studies concerning the use of inhibitors in neuroblastoma, either directly on 
MYCN, as well as indirectly through the inhibition of other molecules. We have summa-
rized the most recent inhibitors and molecules in Table 5. 
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Table 5. Therapeutic targets in neuroblastoma. 
Target Molecule Inhibitor 
MYCN Am-
plification Citation 
MYCN Proto-Oncogene, BHLH Transcrip-





















Yes and No [221] 
Tropomyosin Receptor Kinase C (TrkC) Valproic Acid Yes [224] 
Neuronal Leucine-Rich Repeat 1 (NLRR1) 
Monoclonal Antibodies Against The Extracellular Do-
mains Of NLRR1 (N1mAb) 
Yes [225] 
Mitogen-Activated Protein Kinase Kinase Ki-
nase 3 (MAP3K3) 
Bromodomain-Containing Protein 4 (BRD4) 
miR-3140-3p Yes [226] 




B-Cell Lymphoma 2 (BCL2) Venetoclax Yes [228] 
Cyclin Dependent Kinase 4 (CDK4) 






















Peptidyl-Prolyl Cis/Trans Isomerase (Pin1) Sulfopin  [232] 






Monocarboxylate Transporter 1 (MCT1) AZD3965 Yes [234] 
Histone Deacetylase (HDAC) Suberanoyl Hydroxamic Acid (SAHA) Yes [235] 
Ubiquitin Carboxyl-Terminal Hydrolase 5 
(USP5) 
SE486-11 Yes [235] 
5. Conclusions 
It the present study, we have reviewed the literature for the connection between 
MYCN and neuroblastoma. We have investigated mostly all possible aspects in MYCN 
biology including, the presence of MYCN G-quadraplexes in the gene’s structure, the 
“anatomy” of MYCN’s transcripts, as well as the epigenetic regulation in relation to neu-
roblastoma. MYCN, is one the most well studied genes in neuroblastoma and yet, there is 
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much to be learned on its biology. We have seen that the ontogeny of neuroblastoma is 
closely related to MYCN biology, where the presence of chromosomal aberrations is 
tightly linked to the deletion or the gain of tumor suppressor and oncogenes respectively. 
MYCN, is known to play a significant role in the chromosomal stability of neuroblastoma, 
as well as it is able to change the methylation and acetylation status of the genome and 
the genome-regulatory mechanisms. In that sense, several approaches have attempted to 
exploit the properties of MYCN and its biology, in order to use them as prognostic and 
more importantly therapeutic targets. It is certain that we still need much more research 
in order to comprehend the depth of the disease and exploit that knowledge for its ther-
apy. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/diseases9040078/s1, Table S1: predicted miRNAs as potential targets for the MYCN gene. 
miRNAs were predicted using the miRDB database [125–128]. 
Author Contributions: Conceptualization, G.I.L.; investigation, M.B., K.H., A.Z. and G.I.L.; writ-
ing—original draft preparation, M.B., K.H., G.I.L.; writing—review and editing, A.Z. and G.I.L.; 
visualization, G.I.L.; supervision, G.I.L.; project administration, A.Z. and G.I.L.; funding acquisition, 
A.Z. All authors have read and agreed to the published version of the manuscript. 
Funding: This research received no external funding. 
Institutional Review Board Statement: Not applicable. 
Informed Consent Statement: Not applicable. 
Data Availability Statement: Not applicable. 
Conflicts of Interest: The authors declare no conflicts of interest. 
References 
1. Kohl, N.E.; Kanda, N.; Schreck, R.R.; Bruns, G.; Latt, S.A.; Gilbert, F.; Alt, F.W. Transposition and amplification of oncogene-
related sequences in human neuroblastomas. Cell 1983, 35, 359–367. 
2. Schwab, M.; Alitalo, K.; Klempnauer, K.H.; Varmus, H.E.; Bishop, J.M.; Gilbert, F.; Brodeur, G.; Goldstein, M.; Trent, J. Ampli-
fied DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma 
tumour. Nature 1983, 305, 245–248. 
3. Huang, M.; Weiss, W.A. Neuroblastoma and mycn. Cold Spring Harb. Perspect. Med. 2013, 3, a014415. 
4. Schwab, M.; Varmus, H.E.; Bishop, J.M. Human n-myc gene contributes to neoplastic transformation of mammalian cells in 
culture. Nature 1985, 316, 160–162. 
5. Schwab, M.; Bishop, J.M. Sustained expression of the human protooncogene mycn rescues rat embryo cells from senescence. 
Proc. Natl. Acad. Sci. United States Am. 1988, 85, 9585–9589. 
6. Schweigerer, L.; Scheurich, P.; Fotsis, T. Enhanced mycn oncogene expression in human neuroblastoma cells results in increased 
susceptibility to growth inhibition by tnf alpha. Biochem. Biophys. Res. Commun. 1990, 170, 1301–1307. 
7. VanDevanter, D.R.; Piaskowski, V.D.; Casper, J.T.; Douglass, E.C.; Von Hoff, D.D. Ability of circular extrachromosomal DNA 
molecules to carry amplified mycn proto-oncogenes in human neuroblastomas in vivo. J. Natl. Cancer Inst. 1990, 82, 1815–1821. 
8. Brady, S.W.; Liu, Y.; Ma, X.; Gout, A.M.; Hagiwara, K.; Zhou, X.; Wang, J.; Macias, M.; Chen, X.; Easton, J.; et al. Pan-neuroblas-
toma analysis reveals age- and signature-associated driver alterations. Nat. Commun. 2020, 11, 5183. 
9. Borgenvik, A.; Čančer, M.; Hutter, S.; Swartling, F.J. Targeting mycn in molecularly defined malignant brain tumors. Front. 
Oncol. 2020, 10, 626751. 
10. Gruszka, R.; Zakrzewski, K.; Liberski, P.P.; Zakrzewska, M. Mrna and mirna expression analyses of the myc/e2f/mir-17-92 net-
work in the most common pediatric brain tumors. Int. J. Mol. Sci. 2021, 22, 543. 
11. Raghuram, N.; Khan, S.; Mumal, I.; Bouffet, E.; Huang, A. Embryonal tumors with multi-layered rosettes: A disease of dysreg-
ulated mirnas. J. Neuro-Oncol. 2020, 150, 63–73. 
12. Kumar, R.; Smith, K.S.; Deng, M.; Terhune, C.; Robinson, G.W.; Orr, B.A.; Liu, A.P.Y.; Lin, T.; Billups, C.A.; Chintagumpala, M.; 
et al. Clinical outcomes and patient-matched molecular composition of relapsed medulloblastoma. J. Clin. Oncol. 2021, 39, 807–
821. 
13. Skowron, P.; Farooq, H.; Cavalli, F.M.G.; Morrissy, A.S.; Ly, M.; Hendrikse, L.D.; Wang, E.Y.; Djambazian, H.; Zhu, H.; Mungall, 
K.L.; et al. The transcriptional landscape of shh medulloblastoma. Nat. Commun. 2021, 12, 1749. 
14. Estiar, M.A.; Javan, F.; Zekri, A.; Mehrazin, M.; Mehdipour, P. Prognostic significance of mycn gene amplification and protein 
expression in primary brain tumors: Astrocytoma and meningioma. Cancer Biomark. 2017, 19, 341–351. 
Diseases 2021, 9, 78 31 of 39 
 
 
15. Čančer, M.; Drews, L.F.; Bengtsson, J.; Bolin, S.; Rosén, G.; Westermark, B.; Nelander, S.; Forsberg-Nilsson, K.; Uhrbom, L.; 
Weishaupt, H.; et al. Bet and aurora kinase a inhibitors synergize against mycn-positive human glioblastoma cells. Cell Death 
Dis. 2019, 10, 881. 
16. Wang, B.; Wu, Z.H.; Lou, P.Y.; Chai, C.; Han, S.Y.; Ning, J.F.; Li, M. Human bone marrow-derived mesenchymal stem cell-
secreted exosomes overexpressing microrna-34a ameliorate glioblastoma development via down-regulating mycn. Cell. Oncol. 
2019, 42, 783–799. 
17. Liu, Z.; Chen, S.S.; Clarke, S.; Veschi, V.; Thiele, C.J. Targeting mycn in pediatric and adult cancers. Front. Oncol. 2020, 10, 623679. 
18. Nakazawa, A. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for 
treatment stratification. Pathol. Int. 2021, 71, 232–244. 
19. Alaminos, M.; Gerald, W.L.; Cheung, N.K. Prognostic value of mycn and id2 overexpression in neuroblastoma. Pediatric Blood 
Cancer 2005, 45, 909–915. 
20. Michalowski, M.B.; de Fraipont, F.; Plantaz, D.; Michelland, S.; Combaret, V.; Favrot, M.C. Methylation of tumor-suppressor 
genes in neuroblastoma: The rassf1a gene is almost always methylated in primary tumors. Pediatric Blood Cancer 2008, 50, 29–
32. 
21. Zafar, A.; Wang, W.; Liu, G.; Xian, W.; McKeon, F.; Zhou, J.; Zhang, R. Targeting the p53-mdm2 pathway for neuroblastoma 
therapy: Rays of hope. Cancer Lett. 2021, 496, 16–29. 
22. Jiang, C.Y.; Xu, X.; Jian, B.L.; Zhang, X.; Yue, Z.X.; Guo, W.; Ma, X.L. Chromosome 10 abnormality predicts prognosis of neuro-
blastoma patients with bone marrow metastasis. Ital. J. Pediatrics 2021, 47, 134. 
23. Koh, K.N.; Lee, J.Y.; Lim, J.; Shin, J.; Kang, S.H.; Suh, J.K.; Kim, H.; Im, H.J.; Namgoong, J.M.; Kim, D.Y.; et al. Genetic alterations 
detected by targeted next-generation sequencing and their clinical implications in neuroblastoma. Anticancer Res. 2020, 40, 7057–
7065. 
24. Higashi, M.; Sakai, K.; Fumino, S.; Aoi, S.; Furukawa, T.; Tajiri, T. The roles played by the mycn, trk, and alk genes in neuro-
blastoma and neural development. Surg. Today 2019, 49, 721–727. 
25. Korshunov, A.; Remke, M.; Kool, M.; Hielscher, T.; Northcott, P.A.; Williamson, D.; Pfaff, E.; Witt, H.; Jones, D.T.; Ryzhova, M.; 
et al. Biological and clinical heterogeneity of mycn-amplified medulloblastoma. Acta Neuropathol. 2012, 123, 515–527. 
26. Wright, J.H. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J. Exp. Med. 1910, 12, 556–561. 
27. Matthay, K.K. Neuroblastoma: Biology and therapy. Oncology 1997, 11, 1857–1866; discussion 1869-1872, 1875. 
28. Knudson, A.G., Jr.; Strong, L. Mutation and cancer: Neuroblastoma and pheochromocytoma. Am. J. Hum. Genet. 1972, 24, 514. 
29. Smith, E.I.; Haase, G.M.; Seeger, R.C.; Brodeur, G.M. A surgical perspective on the current staging in neuroblastoma—the in-
ternational neuroblastoma staging system proposal. J. Pediatric Surg. 1989, 24, 386–390. 
30. Wood, L.; Lowis, S. An update on neuroblastoma. Paediatr. Child Health 2008, 18, 123–128. 
31. Seeger, R.C.; Brodeur, G.M.; Sather, H.; Dalton, A.; Siegel, S.E.; Wong, K.Y.; Hammond, D. Association of multiple copies of the 
n-myc oncogene with rapid progression of neuroblastomas. New Engl. J. Med. 1985, 313, 1111–1116. 
32. Ludwig, J.A.; Weinstein, J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845–856. 
33. Brodeur, G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3, 203–216. 
34. Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8, 547–566. 
35. Beltran, H. The n-myc oncogene: Maximizing its targets, regulation, and therapeutic potential. Mol. Cancer Res. 2014, 12, 815–
822. 
36. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R. A census of human cancer 
genes. Nat. Rev. Cancer 2004, 4, 177–183. 
37. Knuutila, S.; Björkqvist, A.-M.; Autio, K.; Tarkkanen, M.; Wolf, M.; Monni, O.; Szymanska, J.; Larramendy, M.L.; Tapper, J.; 
Pere, H.; et al. DNA copy number amplifications in human neoplasms: Review of comparative genomic hybridization studies. 
Am. J. Pathol. 1998, 152, 1107. 
38. Wieland, L.; Engel, K.; Volkmer, I.; Krüger, A.; Posern, G.; Kornhuber, M.E.; Staege, M.S.; Emmer, A. Overexpression of endog-
enous retroviruses and malignancy markers in neuroblastoma cell lines by medium-induced microenvironmental changes. 
Front. Oncol. 2021, 11, 637522. 
39. Sooksawasdi Na Ayudhya, S.; Meijer, A.; Bauer, L.; Oude Munnink, B.; Embregts, C.; Leijten, L.; Siegers, J.Y.; Laksono, B.M.; 
van Kuppeveld, F.; Kuiken, T.; et al. Enhanced enterovirus d68 replication in neuroblastoma cells is associated with a cell cul-
ture-adaptive amino acid substitution in vp1. mSphere 2020, 5, e00941-20. 
40. Dang, C.V. C-myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 1999, 19, 1–11. 
41. Bordow, S.B.; Norris, M.D.; Haber, P.S.; Marshall, G.M.; Haber, M. Prognostic significance of mycn oncogene expression in 
childhood neuroblastoma. J. Clin. Oncol. 1998, 16, 3286–3294. 
42. Strieder, V.; Lutz, W. Regulation of n-myc expression in development and disease. Cancer Lett. 2002, 180, 107–119. 
43. Maris, J.M.; Weiss, M.J.; Guo, C.; Gerbing, R.B.; Stram, D.O.; White, P.S.; Hogarty, M.D.; Sulman, E.P.; Thompson, P.M.; Lukens, 
J.N.; et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival 
probability in neuroblastoma patients: A children’s cancer group study. J. Clin. Oncol. 2000, 18, 1888–1899. 
44. Cohn, S.L.; London, W.B.; Huang, D.; Katzenstein, H.M.; Salwen, H.R.; Reinhart, T.; Madafiglio, J.; Marshall, G.M.; Norris, M.D.; 
Haber, M. Mycn expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified mycn. 
J. Clin. Oncol. 2000, 18, 3604–3613. 
Diseases 2021, 9, 78 32 of 39 
 
 
45. Sato, Y.; Kobayashi, Y.; Sasaki, H.; Toyama, T.; Kondo, S.; Kiriyama, M.; Fujii, Y. Expression of id2 mrna in neuroblastoma and 
normal ganglion. Eur. J. Surg. Oncol. 2003, 29, 284–287. 
46. Pan, L.J.; Chen, J.L.; Wu, Z.X.; Wu, Y.M. Exportin-t: A novel prognostic predictor and potential therapeutic target for neuroblas-
toma. Technol. Cancer Res. Treat. 2021, 20, 15330338211039132. 
47. Irwin, M.S.; Naranjo, A.; Zhang, F.F.; Cohn, S.L.; London, W.B.; Gastier-Foster, J.M.; Ramirez, N.C.; Pfau, R.; Reshmi, S.; Wagner, 
E.; et al. Revised neuroblastoma risk classification system: A report from the children’s oncology group. J. Clin. Oncol. 2021, 39, 
3229–3241. 
48. Zhang, F.; Tian, Z.; Li, T.; Hu, X.; Zhu, J. Prognostic value of c-myc expression in patients with peripheral neuroblastic tumors. 
Int. J. Gen. Med. 2021, 14, 2901–2907. 
49. Wang, H.; Wang, X.; Xu, L.; Zhang, J.; Cao, H. Age related gene dst represents an independent prognostic factor for mycn non-
amplified neuroblastoma. Bmc Pediatrics 2021, 21, 272. 
50. Liao, Y.M.; Hung, T.H.; Tung, J.K.; Yu, J.; Hsu, Y.L.; Hung, J.T.; Yu, A.L. Low expression of il-15 and nkt in tumor microenvi-
ronment predicts poor outcome of mycn-non-amplified neuroblastoma. J. Pers. Med. 2021, 11, 122. 
51. Wolf, E.; Eilers, M. Targeting myc proteins for tumor therapy. Annu. Rev. Cancer Biol. 2020, 4, 61–75. 
52. Liao, Y.; Wang, J.; Jaehnig, E.J.; Shi, Z.; Zhang, B. Webgestalt 2019: Gene set analysis toolkit with revamped uis and apis. Nucleic 
Acids Res. 2019, 47, W199–W205. 
53. Wang, J.; Vasaikar, S.; Shi, Z.; Greer, M.; Zhang, B. Webgestalt 2017: A more comprehensive, powerful, flexible and interactive 
gene set enrichment analysis toolkit. Nucleic Acids Res. 2017, 45, W130–W137. 
54. Wang, J.; Duncan, D.; Shi, Z.; Zhang, B. Web-based gene set analysis toolkit (webgestalt): Update 2013. Nucleic Acids Res. 2013, 
41, W77-W83. 
55. Zhang, B.; Kirov, S.; Snoddy, J. Webgestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic 
Acids Res. 2005, 33, W741–W748. 
56. Richards, M.W.; Burgess, S.G.; Poon, E.; Carstensen, A.; Eilers, M.; Chesler, L.; Bayliss, R. Structural basis of n-myc binding by 
aurora-a and its destabilization by kinase inhibitors. Proc. Natl. Acad. Sci. USA 2016, 113, 13726–13731. 
57. Bannasch, D.; Weis, I.; Schwab, M. Nmi protein interacts with regions that differ between mycn and myc and is localized in the 
cytoplasm of neuroblastoma cells in contrast to nuclear mycn. Oncogene 1999, 18, 6810–6817. 
58. Beierle, E.A.; Trujillo, A.; Nagaram, A.; Kurenova, E.V.; Finch, R.; Ma, X.; Vella, J.; Cance, W.G.; Golubovskaya, V.M. N-myc 
regulates focal adhesion kinase expression in human neuroblastoma. J. Biol. Chem. 2007, 282, 12503–12516. 
59. Ramsay, G.; Stanton, L.; Schwab, M.; Bishop, J.M. Human proto-oncogene n-myc encodes nuclear proteins that bind DNA. Mol. 
Cell. Biol. 1986, 6, 4450–4457. 
60. Gaudet, P.; Livstone, M.S.; Lewis, S.E.; Thomas, P.D. Phylogenetic-based propagation of functional annotations within the gene 
ontology consortium. Brief. Bioinform. 2011, 12, 449–462. 
61. Amente, S.; Gargano, B.; Diolaiti, D.; Della Valle, G.; Lania, L.; Majello, B. P14arf interacts with n-myc and inhibits its transcrip-
tional activity. FEBS Lett. 2007, 581, 821–825. 
62. Bannasch, D.; Mädge, B.; Schwab, M. Functional interaction of yaf2 with the central region of mycn. Oncogene 2001, 20, 5913–
5919. 
63. Brockmann, M.; Poon, E.; Berry, T.; Carstensen, A.; Deubzer, H.E.; Rycak, L.; Jamin, Y.; Thway, K.; Robinson, S.P.; Roels, F.; et 
al. Small molecule inhibitors of aurora-a induce proteasomal degradation of n-myc in childhood neuroblastoma. Cancer Cell 
2013, 24, 75–89. 
64. Dardenne, E.; Beltran, H.; Benelli, M.; Gayvert, K.; Berger, A.; Puca, L.; Cyrta, J.; Sboner, A.; Noorzad, Z.; MacDonald, T.; et al. 
N-myc induces an ezh2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 2016, 30, 563–
577. 
65. Gustafson, W.C.; Meyerowitz, J.G.; Nekritz, E.A.; Chen, J.; Benes, C.; Charron, E.; Simonds, E.F.; Seeger, R.; Matthay, K.K.; Hertz, 
N.T.; et al. Drugging mycn through an allosteric transition in aurora kinase a. Cancer Cell 2014, 26, 414–427. 
66. Liu, T.; Tee, A.E.; Porro, A.; Smith, S.A.; Dwarte, T.; Liu, P.Y.; Iraci, N.; Sekyere, E.; Haber, M.; Norris, M.D.; et al. Activation of 
tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for myc oncogenesis. Proc. 
Natl. Acad. Sci. USA 2007, 104, 18682–18687. 
67. Marshall, G.M.; Liu, P.Y.; Gherardi, S.; Scarlett, C.J.; Bedalov, A.; Xu, N.; Iraci, N.; Valli, E.; Ling, D.; Thomas, W.; et al. Sirt1 
promotes n-myc oncogenesis through a positive feedback loop involving the effects of mkp3 and erk on n-myc protein stability. 
PLoS Genet. 2011, 7, e1002135. 
68. Otto, T.; Horn, S.; Brockmann, M.; Eilers, U.; Schüttrumpf, L.; Popov, N.; Kenney, A.M.; Schulte, J.H.; Beijersbergen, R.; Christi-
ansen, H.; et al. Stabilization of n-myc is a critical function of aurora a in human neuroblastoma. Cancer Cell 2009, 15, 67–78. 
69. Vo, B.T.; Wolf, E.; Kawauchi, D.; Gebhardt, A.; Rehg, J.E.; Finkelstein, D.; Walz, S.; Murphy, B.L.; Youn, Y.H.; Han, Y.G.; et al. 
The interaction of myc with miz1 defines medulloblastoma subgroup identity. Cancer Cell 2016, 29, 5–16. 
70. Yin, Y.; Morgunova, E.; Jolma, A.; Kaasinen, E.; Sahu, B.; Khund-Sayeed, S.; Das, P.K.; Kivioja, T.; Dave, K.; Zhong, F.; et al. 
Impact of cytosine methylation on DNA binding specificities of human transcription factors. Science 2017, 356, eaaj2239, 
doi:10.1126/science.aaj2239. 
71. De Brouwer, S.; Mestdagh, P.; Lambertz, I.; Pattyn, F.; De Paepe, A.; Westermann, F.; Schroeder, C.; Schulte, J.H.; Schramm, A.; 
De Preter, K.; et al. Dickkopf-3 is regulated by the mycn-induced mir-17-92 cluster in neuroblastoma. Int. J. Cancer 2012, 130, 
2591–2598. 
Diseases 2021, 9, 78 33 of 39 
 
 
72. Kumps, C.; Fieuw, A.; Mestdagh, P.; Menten, B.; Lefever, S.; Pattyn, F.; De Brouwer, S.; Sante, T.; Schulte, J.H.; Schramm, A.; et 
al. Focal DNA copy number changes in neuroblastoma target mycn regulated genes. PLoS ONE 2013, 8, e52321. 
73. Suenaga, Y.; Islam, S.M.; Alagu, J.; Kaneko, Y.; Kato, M.; Tanaka, Y.; Kawana, H.; Hossain, S.; Matsumoto, D.; Yamamoto, M.; 
et al. Ncym, a cis-antisense gene of mycn, encodes a de novo evolved protein that inhibits gsk3β resulting in the stabilization 
of mycn in human neuroblastomas. PLoS Genet. 2014, 10, e1003996. 
74. Gellert, M.; Lipsett, M.N.; Davies, D.R. Helix formation by guanylic acid. Proc. Natl. Acad. Sci. USA 1962, 48, 2013–2018. 
75. Routh, E.D.; Creacy, S.D.; Beerbower, P.E.; Akman, S.A.; Vaughn, J.P.; Smaldino, P.J. A g-quadruplex DNA-affinity approach 
for purification of enzymatically active g4 resolvase1. J. Vis. Exp 2017, 121, e55496. 
76. Largy, E.; Mergny, J.L.; Gabelica, V. Role of alkali metal ions in g-quadruplex nucleic acid structure and stability. Met. Ions Life 
Sci. 2016, 16, 203–258. 
77. Sundquist, W.I.; Klug, A. Telomeric DNA dimerizes by formation of guanine tetrads between hairpin loops. Nature 1989, 342, 
825–829. 
78. Sen, D.; Gilbert, W. Formation of parallel four-stranded complexes by guanine-rich motifs in DNA and its implications for 
meiosis. Nature 1988, 334, 364–366. 
79. Han, H.; Hurley, L.H. G-quadruplex DNA: A potential target for anti-cancer drug design. Trends Pharmacol. Sci. 2000, 21, 136–
142. 
80. Wang, W.; Hu, S.; Gu, Y.; Yan, Y.; Stovall, D.B.; Li, D.; Sui, G. Human myc g-quadruplex: From discovery to a cancer therapeutic 
target. Biochim. Biophys. Acta. Rev. Cancer 2020, 1874, 188410. 
81. Kikin, O.; D’Antonio, L.; Bagga, P.S. Qgrs mapper: A web-based server for predicting g-quadruplexes in nucleotide sequences. 
Nucleic Acids Res. 2006, 34, W676–W682. 
82. Trajkovski, M.; da Silva, M.W.; Plavec, J. Unique structural features of interconverting monomeric and dimeric g-quadruplexes 
adopted by a sequence from the intron of the n-myc gene. J. Am. Chem. Soc. 2012, 134, 4132–4141. 
83. Benabou, S.; Ferreira, R.; Aviñó, A.; González, C.; Lyonnais, S.; Solà, M.; Eritja, R.; Jaumot, J.; Gargallo, R. Solution equilibria of 
cytosine- and guanine-rich sequences near the promoter region of the n-myc gene that contain stable hairpins within lateral 
loops. Biochim. Biophys. Acta 2014, 1840, 41–52. 
84. Li, F.; Guo, D.; Kang, L. Study on the recognition of g-quadruplexes by two stereoisomers of alkaloids. Anal. Bioanal. Chem. 2019, 
411, 5555–5561. 
85. Prosperini, A.; Berrada, H.; Ruiz, M.J.; Caloni, F.; Coccini, T.; Spicer, L.J.; Perego, M.C.; Lafranconi, A. A review of the mycotoxin 
enniatin b. Front. Public Health 2017, 5, 304. 
86. Li, F.; Chen, H.; Zhou, J.; Yuan, G. Exploration of the selective recognition of the g-quadruplex in the n-myc oncogene by elec-
trospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2015, 29, 247–252. 
87. Antczak, M.; Popenda, M.; Zok, T.; Sarzynska, J.; Ratajczak, T.; Tomczyk, K.; Adamiak, R.W.; Szachniuk, M. New functionality 
of rnacomposer: An application to shape the axis of mir160 precursor structure. Acta Biochim. Pol. 2016, 63, 737–744. 
88. Popenda, M.; Szachniuk, M.; Antczak, M.; Purzycka, K.J.; Lukasiak, P.; Bartol, N.; Blazewicz, J.; Adamiak, R.W. Automated 3d 
structure composition for large rnas. Nucleic Acids Res. 2012, 40, e112. 
89. Besançon, R.; Valsesia-Wittmann, S.; Locher, C.; Delloye-Bourgeois, C.; Furhman, L.; Tutrone, G.; Bertrand, C.; Jallas, A.C.; Ga-
rin, E.; Puisieux, A. Upstream orf affects mycn translation depending on exon 1b alternative splicing. BMC Cancer 2009, 9, 445. 
90. Yang, M.; Carter, S.; Parmar, S.; Bume, D.D.; Calabrese, D.R.; Liang, X.; Yazdani, K.; Xu, M.; Liu, Z.; Thiele, C.J.; et al. Targeting 
a noncanonical, hairpin-containing g-quadruplex structure from the mycn gene. Nucleic Acids Res. 2021, 49, 7856–7869. 
91. Jacobs, J.F.; van Bokhoven, H.; van Leeuwen, F.N.; Hulsbergen-van de Kaa, C.A.; de Vries, I.J.; Adema, G.J.; Hoogerbrugge, 
P.M.; de Brouwer, A.P. Regulation of mycn expression in human neuroblastoma cells. BMC Cancer 2009, 9, 239. 
92. Stanton, L.W.; Bishop, J.M. Alternative processing of rna transcribed from nmyc. Mol. Cell. Biol. 1987, 7, 4266–4272. 
93. Peirce, S.K.; Findley, H.W. High level mycn expression in non-mycn amplified neuroblastoma is induced by the combination 
treatment nutlin-3 and doxorubicin and enhances chemosensitivity. Oncol. Rep. 2009, 22, 1443–1449. 
94. Cage, T.A.; Chanthery, Y.; Chesler, L.; Grimmer, M.; Knight, Z.; Shokat, K.; Weiss, W.A.; Gustafson, W.C. Downregulation of 
mycn through pi3k inhibition in mouse models of pediatric neural cancer. Front. Oncol. 2015, 5, 111. 
95. Ruiz-Pérez, M.V.; Henley, A.B.; Arsenian-Henriksson, M. The mycn protein in health and disease. Genes 2017, 8, 113. 
96. Bell, E.; Chen, L.; Liu, T.; Marshall, G.M.; Lunec, J.; Tweddle, D.A. Mycn oncoprotein targets and their therapeutic potential. 
Cancer Lett. 2010, 293, 144–157. 
97. Ham, J.; Costa, C.; Sano, R.; Lochmann, T.L.; Sennott, E.M.; Patel, N.U.; Dastur, A.; Gomez-Caraballo, M.; Krytska, K.; Hata, 
A.N.; et al. Exploitation of the apoptosis-primed state of mycn-amplified neuroblastoma to develop a potent and specific tar-
geted therapy combination. Cancer Cell 2016, 29, 159–172. 
98. Cortés, C.; Kozma, S.C.; Tauler, A.; Ambrosio, S. Mycn concurrence with saha-induced cell death in human neuroblastoma cells. 
Cell. Oncol. 2015, 38, 341–352. 
99. DeBerardinis, R.J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C.B. Beyond aerobic glycolysis: 
Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. 
Natl. Acad. Sci. USA 2007, 104, 19345–19350. 
100. Qing, G.; Li, B.; Vu, A.; Skuli, N.; Walton, Z.E.; Liu, X.; Mayes, P.A.; Wise, D.R.; Thompson, C.B.; Maris, J.M.; et al. Atf4 regulates 
myc-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012, 22, 631–644. 
Diseases 2021, 9, 78 34 of 39 
 
 
101. Pinkel, D.; Segraves, R.; Sudar, D.; Clark, S.; Poole, I.; Kowbel, D.; Collins, C.; Kuo, W.L.; Chen, C.; Zhai, Y.; et al. High resolution 
analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 1998, 20, 207–
211. 
102. Walker, C.; Joyce, K.A.; Thompson-Hehir, J.; Davies, M.P.; Gibbs, F.E.; Halliwell, N.; Lloyd, B.H.; Machell, Y.; Roebuck, M.M.; 
Salisbury, J.; et al. Characterisation of molecular alterations in microdissected archival gliomas. Acta Neuropathol. 2001, 101, 321–
333. 
103. Kaneko, Y.; Knudson, A.G. Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosomes Cancer 2000, 29, 89–95. 
104. Ladenstein, R.; Ambros, I.M.; Potschger, U.; Amann, G.; Urban, C.; Fink, F.M.; Schmitt, K.; Jones, R.; Slociak, M.; Schilling, F.; et 
al. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med. Pediatr. Oncol. 2001, 36, 83–92. 
105. Fujita, T.; Igarashi, J.; Okawa, E.R.; Gotoh, T.; Manne, J.; Kolla, V.; Kim, J.; Zhao, H.; Pawel, B.R.; London, W.B.; et al. Chd5, a 
tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst. 2008, 100, 940–949. 
106. Schwab, M.; Westermann, F.; Hero, B.; Berthold, F. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet 
Oncol 2003, 4, 472–480. 
107. Van Roy, N.; De Preter, K.; Hoebeeck, J.; Van Maerken, T.; Pattyn, F.; Mestdagh, P.; Vermeulen, J.; Vandesompele, J.; Speleman, 
F. The emerging molecular pathogenesis of neuroblastoma: Implications for improved risk assessment and targeted therapy. 
Genome Med 2009, 1, 74. 
108. White, P.S.; Thompson, P.M.; Gotoh, T.; Okawa, E.R.; Igarashi, J.; Kok, M.; Winter, C.; Gregory, S.G.; Hogarty, M.D.; Maris, J.M.; 
et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005, 24, 2684–2694. 
109. Michels, E.; Hoebeeck, J.; De Preter, K.; Schramm, A.; Brichard, B.; De Paepe, A.; Eggert, A.; Laureys, G.; Vandesompele, J.; 
Speleman, F. Cadm1 is a strong neuroblastoma candidate gene that maps within a 3.72 mb critical region of loss on 11q23. BMC 
Cancer 2008, 8, 173. 
110. Mosse, Y.P.; Diskin, S.J.; Wasserman, N.; Rinaldi, K.; Attiyeh, E.F.; Cole, K.; Jagannathan, J.; Bhambhani, K.; Winter, C.; Maris, 
J.M. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes 
Chromosomes Cancer 2007, 46, 936–949. 
111. Berry, T.; Luther, W.; Bhatnagar, N.; Jamin, Y.; Poon, E.; Sanda, T.; Pei, D.; Sharma, B.; Vetharoy, W.R.; Hallsworth, A.; et al. The 
alk(f1174l) mutation potentiates the oncogenic activity of mycn in neuroblastoma. Cancer Cell 2012, 22, 117–130. 
112. Cazes, A.; Lopez-Delisle, L.; Tsarovina, K.; Pierre-Eugene, C.; De Preter, K.; Peuchmaur, M.; Nicolas, A.; Provost, C.; Louis-
Brennetot, C.; Daveau, R.; et al. Activated alk triggers prolonged neurogenesis and ret upregulation providing a therapeutic 
target in alk-mutated neuroblastoma. Oncotarget 2014, 5, 2688–2702. 
113. George, R.E.; Sanda, T.; Hanna, M.; Frohling, S.; Luther, W., 2nd; Zhang, J.; Ahn, Y.; Zhou, W.; London, W.B.; McGrady, P.; et 
al. Activating mutations in alk provide a therapeutic target in neuroblastoma. Nature 2008, 455, 975–978. 
114. Janoueix-Lerosey, I.; Lequin, D.; Brugieres, L.; Ribeiro, A.; de Pontual, L.; Combaret, V.; Raynal, V.; Puisieux, A.; Schleiermacher, 
G.; Pierron, G.; et al. Somatic and germline activating mutations of the alk kinase receptor in neuroblastoma. Nature 2008, 455, 
967–970. 
115. Mosse, Y.P.; Laudenslager, M.; Longo, L.; Cole, K.A.; Wood, A.; Attiyeh, E.F.; Laquaglia, M.J.; Sennett, R.; Lynch, J.E.; Perri, P.; 
et al. Identification of alk as a major familial neuroblastoma predisposition gene. Nature 2008, 455, 930–935. 
116. Ogawa, S.; Takita, J.; Sanada, M.; Hayashi, Y. Oncogenic mutations of alk in neuroblastoma. Cancer Sci 2011, 102, 302–308. 
117. Pugh, T.J.; Morozova, O.; Attiyeh, E.F.; Asgharzadeh, S.; Wei, J.S.; Auclair, D.; Carter, S.L.; Cibulskis, K.; Hanna, M.; Kiezun, A.; 
et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 2013, 45, 279–284. 
118. Schulte, J.H.; Lindner, S.; Bohrer, A.; Maurer, J.; De Preter, K.; Lefever, S.; Heukamp, L.; Schulte, S.; Molenaar, J.; Versteeg, R.; 
et al. Mycn and alkf1174l are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2013, 
32, 1059–1065. 
119. Abel, F.; Dalevi, D.; Nethander, M.; Jornsten, R.; De Preter, K.; Vermeulen, J.; Stallings, R.; Kogner, P.; Maris, J.; Nilsson, S. A 6-
gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int. 2011, 11, 9. 
120. Brodeur, G.M.; Iyer, R.; Croucher, J.L.; Zhuang, T.; Higashi, M.; Kolla, V. Therapeutic targets for neuroblastomas. Expert Opin. 
Targets 2014, 18, 277–292. 
121. Bartel, D.P. Metazoan micrornas. Cell 2018, 173, 20–51. 
122. Bartel, D.P. Micrornas: Target recognition and regulatory functions. Cell 2009, 136, 215–233. 
123. Fabian, M.R.; Sonenberg, N.; Filipowicz, W. Regulation of mrna translation and stability by micrornas. Annu. Rev. Biochem. 2010, 
79, 351–379. 
124. Misiak, D.; Hagemann, S.; Bell, J.L.; Busch, B.; Lederer, M.; Bley, N.; Schulte, J.H.; Hüttelmaier, S. The microrna landscape of 
mycn-amplified neuroblastoma. Front. Oncol. 2021, 11, 647737. 
125. Wang, X. Improving microrna target prediction by modeling with unambiguously identified microrna-target pairs from clip-
ligation studies. Bioinformatics 2016, 32, 1316–1322. 
126. Wong, N.; Wang, X. Mirdb: An online resource for microrna target prediction and functional annotations. Nucleic Acids Res. 
2015, 43, D146–D152. 
127. Wang, X.; El Naqa, I.M. Prediction of both conserved and nonconserved microrna targets in animals. Bioinformatics 2008, 24, 
325–332. 
128. Wang, X. Mirdb: A microrna target prediction and functional annotation database with a wiki interface. Rna 2008, 14, 1012–
1017. 
Diseases 2021, 9, 78 35 of 39 
 
 
129. Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. Mirbase: From microrna sequences to function. Nucleic Acids Res. 2019, 47, 
D155–D162. 
130. Kozomara, A.; Griffiths-Jones, S. Mirbase: Annotating high confidence micrornas using deep sequencing data. Nucleic Acids Res. 
2014, 42, D68–D73. 
131. Kozomara, A.; Griffiths-Jones, S. Mirbase: Integrating microrna annotation and deep-sequencing data. Nucleic Acids Res. 2011, 
39, D152–D157. 
132. Griffiths-Jones, S.; Saini, H.K.; van Dongen, S.; Enright, A.J. Mirbase: Tools for microrna genomics. Nucleic Acids Res. 2008, 36, 
D154–D158. 
133. Griffiths-Jones, S.; Grocock, R.J.; van Dongen, S.; Bateman, A.; Enright, A.J. Mirbase: Microrna sequences, targets and gene 
nomenclature. Nucleic Acids Res. 2006, 34, D140–D144. 
134. Griffiths-Jones, S. The microrna registry. Nucleic Acids Res. 2004, 32, D109–D111. 
135. Mogilyansky, E.; Rigoutsos, I. The mir-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increas-
ingly important and numerous roles in health and disease. Cell Death Differ. 2013, 20, 1603–1614. 
136. Buechner, J.; Tømte, E.; Haug, B.H.; Henriksen, J.R.; Løkke, C.; Flægstad, T.; Einvik, C. Tumour-suppressor micrornas let-7 and 
mir-101 target the proto-oncogene mycn and inhibit cell proliferation in mycn-amplified neuroblastoma. Br. J. Cancer 2011, 105, 
296–303. 
137. Zhao, Z.; Ma, X.; Shelton, S.D.; Sung, D.C.; Li, M.; Hernandez, D.; Zhang, M.; Losiewicz, M.D.; Chen, Y.; Pertsemlidis, A.; et al. 
A combined gene expression and functional study reveals the crosstalk between n-myc and differentiation-inducing micrornas 
in neuroblastoma cells. Oncotarget 2016, 7, 79372–79387. 
138. Cole, K.A.; Attiyeh, E.F.; Mosse, Y.P.; Laquaglia, M.J.; Diskin, S.J.; Brodeur, G.M.; Maris, J.M. A functional screen identifies mir-
34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 2008, 6, 735–742. 
139. Di Paolo, D.; Pastorino, F.; Brignole, C.; Corrias, M.V.; Emionite, L.; Cilli, M.; Tamma, R.; Priddy, L.; Amaro, A.; Ferrari, D.; et 
al. Combined replenishment of mir-34a and let-7b by targeted nanoparticles inhibits tumor growth in neuroblastoma preclinical 
models. Small 2020, 16, e1906426. 
140. Soni, K.; Gupta, S.; Gokhale, S.S.; Dey, R.; Gunjal, A.D.; Kumar, V.A.; Pillai, B. Detection and knockdown of microrna-34a using 
thioacetamido nucleic acid. Nucleic Acid Ther. 2013, 23, 195–202. 
141. Stallings, R.L. Microrna involvement in the pathogenesis of neuroblastoma: Potential for microrna mediated therapeutics. Curr. 
Pharm. Des. 2009, 15, 456–462. 
142. Wei, J.S.; Song, Y.K.; Durinck, S.; Chen, Q.R.; Cheuk, A.T.; Tsang, P.; Zhang, Q.; Thiele, C.J.; Slack, A.; Shohet, J.; et al. The mycn 
oncogene is a direct target of mir-34a. Oncogene 2008, 27, 5204–5213. 
143. Li, Y.G.; He, J.H.; Yu, L.; Hang, Z.P.; Li, W.; Shun, W.H.; Huang, G.X. Microrna-202 suppresses mycn expression under the 
control of e2f1 in the neuroblastoma cell line lan-5. Mol. Med. Rep. 2014, 9, 541–546. 
144. Lynch, J.; Fay, J.; Meehan, M.; Bryan, K.; Watters, K.M.; Murphy, D.M.; Stallings, R.L. Mirna-335 suppresses neuroblastoma cell 
invasiveness by direct targeting of multiple genes from the non-canonical tgf-β signalling pathway. Carcinogenesis 2012, 33, 976–
985. 
145. Liu, H.J.; Li, G.L.; Lei, P.C. [effects of mir-144 on proliferation, apoptosis and cisplatin resistance by targeting mycn in pediatric 
neuroblastoma]. Zhonghua Zhong Liu Za Zhi 2019, 41, 516–521. 
146. Ramaiah, M.J.; Pushpavalli, S.N.; Lavanya, A.; Bhadra, K.; Haritha, V.; Patel, N.; Tamboli, J.R.; Kamal, A.; Bhadra, U.; Pal-
Bhadra, M. Novel anthranilamide-pyrazolo [1,5-a]pyrimidine conjugates modulate the expression of p53-mycn associated mi-
cro rnas in neuroblastoma cells and cause cell cycle arrest and apoptosis. Bioorganic Med. Chem. Lett. 2013, 23, 5699–5706. 
147. Gan, L.; Xiu, R.; Ren, P.; Yue, M.; Su, H.; Guo, G.; Xiao, D.; Yu, J.; Jiang, H.; Liu, H.; et al. Metabolic targeting of oncogene myc 
by selective activation of the proton-coupled monocarboxylate family of transporters. Oncogene 2016, 35, 3037–3048. 
148. Cheung, I.Y.; Farazi, T.A.; Ostrovnaya, I.; Xu, H.; Tran, H.; Mihailovic, A.; Tuschl, T.; Cheung, N.K. Deep microrna sequencing 
reveals downregulation of mir-29a in neuroblastoma central nervous system metastasis. Genes Chromosomes Cancer 2014, 53, 
803–814. 
149. Teitz, T.; Inoue, M.; Valentine, M.B.; Zhu, K.; Rehg, J.E.; Zhao, W.; Finkelstein, D.; Wang, Y.D.; Johnson, M.D.; Calabrese, C.; et 
al. Th-mycn mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res. 2013, 
73, 4086–4097. 
150. Cheng, J.; Xu, L.; Deng, L.; Xue, L.; Meng, Q.; Wei, F.; Wang, J. Rna n(6)-methyladenosine modification is required for mir-
98/mycn axis-mediated inhibition of neuroblastoma progression. Sci. Rep. 2020, 10, 13624. 
151. Zhao, J.; Zhou, K.; Ma, L.; Zhang, H. Microrna-145 overexpression inhibits neuroblastoma tumorigenesis in vitro and in vivo. 
Bioengineered 2020, 11, 219–228. 
152. Lovén, J.; Zinin, N.; Wahlström, T.; Müller, I.; Brodin, P.; Fredlund, E.; Ribacke, U.; Pivarcsi, A.; Påhlman, S.; Henriksson, M. 
Mycn-regulated micrornas repress estrogen receptor-alpha (esr1) expression and neuronal differentiation in human neuroblas-
toma. Proc. Natl. Acad. Sci. USA 2010, 107, 1553–1558. 
153. Roth, S.A.; Hald, Ø.H.; Fuchs, S.; Løkke, C.; Mikkola, I.; Flægstad, T.; Schulte, J.; Einvik, C. Microrna-193b-3p represses neuro-
blastoma cell growth via downregulation of cyclin d1, mcl-1 and mycn. Oncotarget 2018, 9, 18160–18179. 
154. Schulte, J.H.; Horn, S.; Otto, T.; Samans, B.; Heukamp, L.C.; Eilers, U.C.; Krause, M.; Astrahantseff, K.; Klein-Hitpass, L.; Buett-
ner, R.; et al. Mycn regulates oncogenic micrornas in neuroblastoma. Int. J. Cancer 2008, 122, 699–704. 
Diseases 2021, 9, 78 36 of 39 
 
 
155. Samaraweera, L.; Spengler, B.A.; Ross, R.A. Reciprocal antagonistic regulation of n-myc mrna by mir-17 and the neuronal-
specific rna-binding protein hud. Oncol. Rep. 2017, 38, 545–550. 
156. Claeys, S.; Denecker, G.; Durinck, K.; Decaesteker, B.; Mus, L.M.; Loontiens, S.; Vanhauwaert, S.; Althoff, K.; Wigerup, C.; Bexell, 
D.; et al. Alk positively regulates mycn activity through repression of hbp1 expression. Oncogene 2019, 38, 2690–2705. 
157. Naraparaju, K.; Kolla, V.; Zhuang, T.; Higashi, M.; Iyer, R.; Kolla, S.; Okawa, E.R.; Blobel, G.A.; Brodeur, G.M. Role of micrornas 
in epigenetic silencing of the chd5 tumor suppressor gene in neuroblastomas. Oncotarget 2016, 7, 15977–15985. 
158. Buechner, J.; Henriksen, J.R.; Haug, B.H.; Tømte, E.; Flaegstad, T.; Einvik, C. Inhibition of mir-21, which is up-regulated during 
mycn knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Differ. Res. Biol. Divers. 
2011, 81, 25–34. 
159. Westerlund, I.; Shi, Y.; Toskas, K.; Fell, S.M.; Li, S.; Surova, O.; Södersten, E.; Kogner, P.; Nyman, U.; Schlisio, S.; et al. Combined 
epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links hif2α to tumor suppression. 
Proc. Natl. Acad. Sci. USA 2017, 114, E6137–E6146. 
160. Parodi, F.; Carosio, R.; Ragusa, M.; Di Pietro, C.; Maugeri, M.; Barbagallo, D.; Sallustio, F.; Allemanni, G.; Pistillo, M.P.; Casciano, 
I.; et al. Epigenetic dysregulation in neuroblastoma: A tale of mirnas and DNA methylation. Biochim. Biophys. Acta 2016, 1859, 
1502–1514. 
161. Uekusa, S.; Kawashima, H.; Sugito, K.; Yoshizawa, S.; Shinojima, Y.; Igarashi, J.; Ghosh, S.; Wang, X.; Fujiwara, K.; Ikeda, T.; et 
al. Nr4a3, a possibile oncogenic factor for neuroblastoma associated with cpgi methylation within the third exon. Int. J. Oncol. 
2014, 44, 1669–1677. 
162. Asada, K.; Watanabe, N.; Nakamura, Y.; Ohira, M.; Westermann, F.; Schwab, M.; Nakagawara, A.; Ushijima, T. Stronger prog-
nostic power of the cpg island methylator phenotype than methylation of individual genes in neuroblastomas. JPN J. Clin. Oncol. 
2013, 43, 641–645. 
163. Hoebeeck, J.; Michels, E.; Pattyn, F.; Combaret, V.; Vermeulen, J.; Yigit, N.; Hoyoux, C.; Laureys, G.; De Paepe, A.; Speleman, 
F.; et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett. 2009, 273, 336–346. 
164. Yan, P.; Mühlethaler, A.; Bourloud, K.B.; Beck, M.N.; Gross, N. Hypermethylation-mediated regulation of cd44 gene expression 
in human neuroblastoma. GenesChromosomes Cancer 2003, 36, 129–138. 
165. Korshunov, A.; Okonechnikov, K.; Schmitt-Hoffner, F.; Ryzhova, M.; Sahm, F.; Stichel, D.; Schrimpf, D.; Reuss, D.E.; Sievers, P.; 
Suwala, A.K.; et al. Molecular analysis of pediatric cns-pnet revealed nosologic heterogeneity and potent diagnostic markers 
for cns neuroblastoma with foxr2-activation. Acta Neuropathol. Commun. 2021, 9, 20. 
166. Schmitt-Hoffner, F.; van Rijn, S.; Toprak, U.H.; Mauermann, M.; Rosemann, F.; Heit-Mondrzyk, A.; Hübner, J.M.; Camgöz, A.; 
Hartlieb, S.; Pfister, S.M.; et al. Foxr2 stabilizes mycn protein and identifies non-mycn-amplified neuroblastoma patients with 
unfavorable outcome. J. Clin. Oncol. 2021, 39, 3217–3228. 
167. Colmenero-Repiso, A.; Gómez-Muñoz, M.A.; Rodríguez-Prieto, I.; Amador-Álvarez, A.; Henrich, K.O.; Pascual-Vaca, D.; 
Okonechnikov, K.; Rivas, E.; Westermann, F.; Pardal, R.; et al. Identification of vrk1 as a new neuroblastoma tumor progression 
marker regulating cell proliferation. Cancers 2020, 12, 3465. 
168. Lin, H.Y.; Chuang, J.H.; Wang, P.W.; Lin, T.K.; Wu, M.T.; Hsu, W.M.; Chuang, H.C. 5-aza-2’-deoxycytidine induces a rig-i-
related innate immune response by modulating mitochondria stress in neuroblastoma. Cells 2020, 9, 1920. 
169. Gupta, S.; Doyle, K.; Mosbruger, T.L.; Butterfield, A.; Weston, A.; Ast, A.; Kaadige, M.; Verma, A.; Sharma, S. Reversible lsd1 
inhibition with hci-2509 induces the p53 gene expression signature and disrupts the mycn signature in high-risk neuroblastoma 
cells. Oncotarget 2018, 9, 9907–9924. 
170. Wong, M.; Tee, A.E.L.; Milazzo, G.; Bell, J.L.; Poulos, R.C.; Atmadibrata, B.; Sun, Y.; Jing, D.; Ho, N.; Ling, D.; et al. The histone 
methyltransferase dot1l promotes neuroblastoma by regulating gene transcription. Cancer Res. 2017, 77, 2522–2533. 
171. Liu, P.Y.; Atmadibrata, B.; Mondal, S.; Tee, A.E.; Liu, T. Ncym is upregulated by lncusmycn and modulates n-myc expression. 
Int. J. Oncol. 2016, 49, 2464–2470. 
172. Henrich, K.O.; Bender, S.; Saadati, M.; Dreidax, D.; Gartlgruber, M.; Shao, C.; Herrmann, C.; Wiesenfarth, M.; Parzonka, M.; 
Wehrmann, L.; et al. Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in un-
favorable neuroblastomas. Cancer Res. 2016, 76, 5523–5537. 
173. Fabian, J.; Opitz, D.; Althoff, K.; Lodrini, M.; Hero, B.; Volland, R.; Beckers, A.; de Preter, K.; Decock, A.; Patil, N.; et al. Mycn 
and hdac5 transcriptionally repress cd9 to trigger invasion and metastasis in neuroblastoma. Oncotarget 2016, 7, 66344–66359. 
174. Ikram, F.; Ackermann, S.; Kahlert, Y.; Volland, R.; Roels, F.; Engesser, A.; Hertwig, F.; Kocak, H.; Hero, B.; Dreidax, D.; et al. 
Transcription factor activating protein 2 beta (tfap2b) mediates noradrenergic neuronal differentiation in neuroblastoma. Mol. 
Oncol. 2016, 10, 344–359. 
175. Sun, Y.; Bell, J.L.; Carter, D.; Gherardi, S.; Poulos, R.C.; Milazzo, G.; Wong, J.W.; Al-Awar, R.; Tee, A.E.; Liu, P.Y.; et al. Wdr5 
supports an n-myc transcriptional complex that drives a protumorigenic gene expression signature in neuroblastoma. Cancer 
Res. 2015, 75, 5143–5154. 
176. Yáñez, Y.; Grau, E.; Rodríguez-Cortez, V.C.; Hervás, D.; Vidal, E.; Noguera, R.; Hernández, M.; Segura, V.; Cañete, A.; Conesa, 
A.; et al. Two independent epigenetic biomarkers predict survival in neuroblastoma. Clin. Epigenetics 2015, 7, 16. 
177. Gonzalez-Gomez, P.; Bello, M.J.; Lomas, J.; Arjona, D.; Alonso, M.E.; Amiñoso, C.; Lopez-Marin, I.; Anselmo, N.P.; Sarasa, J.L.; 
Gutierrez, M.; et al. Aberrant methylation of multiple genes in neuroblastic tumours. Relationship with mycn amplification and 
allelic status at 1p. Eur. J. Cancer 2003, 39, 1478–1485. 
Diseases 2021, 9, 78 37 of 39 
 
 
178. Dreidax, D.; Bannert, S.; Henrich, K.O.; Schröder, C.; Bender, S.; Oakes, C.C.; Lindner, S.; Schulte, J.H.; Duffy, D.; Schwarzl, T.; 
et al. P19-ink4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in 
mycn-amplified neuroblastomas. Hum. Mol. Genet. 2014, 23, 6826–6837. 
179. Haruta, M.; Kamijo, T.; Nakagawara, A.; Kaneko, Y. Rassf1a methylation may have two biological roles in neuroblastoma tu-
morigenesis depending on the ploidy status and age of patients. Cancer Lett. 2014, 348, 167–176. 
180. Lázcoz, P.; Muñoz, J.; Nistal, M.; Pestaña, A.; Encío, I.; Castresana, J.S. Frequent promoter hypermethylation of rassf1a and 
casp8 in neuroblastoma. BMC Cancer 2006, 6, 254. 
181. Yang, Q.; Zage, P.; Kagan, D.; Tian, Y.; Seshadri, R.; Salwen, H.R.; Liu, S.; Chlenski, A.; Cohn, S.L. Association of epigenetic 
inactivation of rassf1a with poor outcome in human neuroblastoma. Clin. Cancer Res. 2004, 10, 8493–8500. 
182. Fulda, S.; Poremba, C.; Berwanger, B.; Häcker, S.; Eilers, M.; Christiansen, H.; Hero, B.; Debatin, K.M. Loss of caspase-8 expres-
sion does not correlate with mycn amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res. 2006, 66, 10016–
10023. 
183. Casciano, I.; Banelli, B.; Croce, M.; De Ambrosis, A.; di Vinci, A.; Gelvi, I.; Pagnan, G.; Brignole, C.; Allemanni, G.; Ferrini, S.; et 
al. Caspase-8 gene expression in neuroblastoma. Ann. New York Acad. Sci. 2004, 1028, 157–167. 
184. Sugito, K.; Kawashima, H.; Yoshizawa, S.; Uekusa, S.; Hoshi, R.; Furuya, T.; Kaneda, H.; Hosoda, T.; Konuma, N.; Masuko, T.; 
et al. Non-promoter DNA hypermethylation of zygote arrest 1 (zar1) in neuroblastomas. J. Pediatr. Surg. 2013, 48, 782–788. 
185. Casalà, C.; Gil-Guiñón, E.; Ordóñez, J.L.; Miguel-Queralt, S.; Rodríguez, E.; Galván, P.; Lavarino, C.; Munell, F.; de Alava, E.; 
Mora, J.; et al. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas 
and its reactivation induces erk1/2-dependent apoptosis. Carcinogenesis 2013, 34, 268–276. 
186. Decock, A.; Ongenaert, M.; Hoebeeck, J.; De Preter, K.; Van Peer, G.; Van Criekinge, W.; Ladenstein, R.; Schulte, J.H.; Noguera, 
R.; Stallings, R.L.; et al. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation bi-
omarkers. Genome Biol. 2012, 13, R95. 
187. Lau, D.T.; Hesson, L.B.; Norris, M.D.; Marshall, G.M.; Haber, M.; Ashton, L.J. Prognostic significance of promoter DNA meth-
ylation in patients with childhood neuroblastoma. Clin. Cancer Res. 2012, 18, 5690–5700. 
188. Sugito, K.; Kawashima, H.; Uekusa, S.; Yoshizawa, S.; Hoshi, R.; Furuya, T.; Kaneda, H.; Hosoda, T.; Masuko, T.; Ohashi, K.; et 
al. Identification of aberrant methylation regions in neuroblastoma by screening of tissue-specific differentially methylated re-
gions. Pediatric Blood Cancer 2013, 60, 383–389. 
189. Djos, A.; Martinsson, T.; Kogner, P.; Carén, H. The rassf gene family members rassf5, rassf6 and rassf7 show frequent DNA 
methylation in neuroblastoma. Mol. Cancer 2012, 11, 40. 
190. Misawa, A.; Tanaka, S.; Yagyu, S.; Tsuchiya, K.; Iehara, T.; Sugimoto, T.; Hosoi, H. Rassf1a hypermethylation in pretreatment 
serum DNA of neuroblastoma patients: A prognostic marker. Br. J. Cancer 2009, 100, 399–404. 
191. Gumy-Pause, F.; Pardo, B.; Khoshbeen-Boudal, M.; Ansari, M.; Gayet-Ageron, A.; Sappino, A.P.; Attiyeh, E.F.; Ozsahin, H. 
Gstp1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. 
GenesChromosomes Cancer 2012, 51, 174–185. 
192. Nair, P.N.; McArdle, L.; Cornell, J.; Cohn, S.L.; Stallings, R.L. High-resolution analysis of 3p deletion in neuroblastoma and 
differential methylation of the sema3b tumor suppressor gene. Cancer Genet. Cytogenet. 2007, 174, 100–110. 
193. Lázcoz, P.; Muñoz, J.; Nistal, M.; Pestaña, A.; Encío, I.J.; Castresana, J.S. Loss of heterozygosity and microsatellite instability on 
chromosome arm 10q in neuroblastoma. Cancer Genet. Cytogenet. 2007, 174, 1–8. 
194. Erdreich-Epstein, A.; Singh, A.R.; Joshi, S.; Vega, F.M.; Guo, P.; Xu, J.; Groshen, S.; Ye, W.; Millard, M.; Campan, M.; et al. 
Association of high microvessel alphavbeta3 and low pten with poor outcome in stage 3 neuroblastoma: Rationale for using 
first in class dual pi3k/brd4 inhibitor, sf1126. Oncotarget 2017, 8, 52193–52210. 
195. Choi, J.H.; Jeong, Y.J.; Yu, A.R.; Yoon, K.S.; Choe, W.; Ha, J.; Kim, S.S.; Yeo, E.J.; Kang, I. Fluoxetine induces apoptosis through 
endoplasmic reticulum stress via mitogen-activated protein kinase activation and histone hyperacetylation in sk-n-be(2)-m17 
human neuroblastoma cells. Apoptosis Int. J. Program. Cell Death 2017, 22, 1079–1097. 
196. Wang, S.S.; Hsiao, R.; Limpar, M.M.; Lomahan, S.; Tran, T.A.; Maloney, N.J.; Ikegaki, N.; Tang, X.X. Destabilization of myc/mycn 
by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin. Int. J. Mol. Med. 2014, 33, 35–42. 
197. Hegarty, S.V.; Togher, K.L.; O’Leary, E.; Solger, F.; Sullivan, A.M.; O’Keeffe, G.W. Romidepsin induces caspase-dependent cell 
death in human neuroblastoma cells. Neurosci. Lett. 2017, 653, 12–18. 
198. Fabian, J.; Lodrini, M.; Oehme, I.; Schier, M.C.; Thole, T.M.; Hielscher, T.; Kopp-Schneider, A.; Opitz, L.; Capper, D.; von 
Deimling, A.; et al. Grhl1 acts as tumor suppressor in neuroblastoma and is negatively regulated by mycn and hdac3. Cancer 
Res. 2014, 74, 2604–2616. 
199. Cheung, N.K.; Dyer, M.A. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 
2013, 13, 397–411. 
200. Brodeur, G.M.; Seeger, R.C.; Schwab, M.; Varmus, H.E.; Bishop, J.M. Amplification of n-myc in untreated human neuroblasto-
mas correlates with advanced disease stage. Science 1984, 224, 1121–1124. 
201. Chen, L.; Iraci, N.; Gherardi, S.; Gamble, L.D.; Wood, K.M.; Perini, G.; Lunec, J.; Tweddle, D.A. P53 is a direct transcriptional 
target of mycn in neuroblastoma. Cancer Res. 2010, 70, 1377–1388. 
202. Helmsauer, K.; Valieva, M.E.; Ali, S.; Chamorro González, R.; Schöpflin, R.; Röefzaad, C.; Bei, Y.; Dorado Garcia, H.; Rodriguez-
Fos, E.; Puiggròs, M.; et al. Enhancer hijacking determines extrachromosomal circular mycn amplicon architecture in neuro-
blastoma. Nat. Commun. 2020, 11, 5823. 
Diseases 2021, 9, 78 38 of 39 
 
 
203. George, R.E.; London, W.B.; Cohn, S.L.; Maris, J.M.; Kretschmar, C.; Diller, L.; Brodeur, G.M.; Castleberry, R.P.; Look, A.T. 
Hyperdiploidy plus nonamplified mycn confers a favorable prognosis in children 12 to 18 months old with disseminated neu-
roblastoma: A pediatric oncology group study. J. Clin. 2005, 23, 6466–6473. 
204. Maris, J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatrics 2005, 17, 7–13. 
205. Schmidt, M.L.; Lal, A.; Seeger, R.C.; Maris, J.M.; Shimada, H.; O’Leary, M.; Gerbing, R.B.; Matthay, K.K. Favorable prognosis 
for patients 12 to 18 months of age with stage 4 nonamplified mycn neuroblastoma: A children’s cancer group study. J. Clin. 
Oncol. 2005, 23, 6474–6480. 
206. Cohn, S.L.; Pearson, A.D.; London, W.B.; Monclair, T.; Ambros, P.F.; Brodeur, G.M.; Faldum, A.; Hero, B.; Iehara, T.; Machin, 
D.; et al. The international neuroblastoma risk group (inrg) classification system: An inrg task force report. J. Clin. Oncol. 2009, 
27, 289–297. 
207. Godfried, M.B.; Veenstra, M.; v Sluis, P.; Boon, K.; v Asperen, R.; Hermus, M.C.; v Schaik, B.D.; Voute, T.P.; Schwab, M.; Ver-
steeg, R.; et al. The n-myc and c-myc downstream pathways include the chromosome 17q genes nm23-h1 and nm23-h2. Onco-
gene 2002, 21, 2097–2101. 
208. Akhavanfard, S.; Nohr, E.; AlNajjar, M.; Haughn, M.; Hashimoto, S.; Deeg, C.; Pfau, R.; Brundler, M.A.; Reshmi, S.C. 5′ alk 
amplification in neuroblastoma: A case report. Case Rep. Oncol. 2021, 14, 585–591. 
209. Bellini, A.; Pötschger, U.; Bernard, V.; Lapouble, E.; Baulande, S.; Ambros, P.F.; Auger, N.; Beiske, K.; Bernkopf, M.; Betts, D.R.; 
et al. Frequency and prognostic impact of alk amplifications and mutations in the european neuroblastoma study group (siopen) 
high-risk neuroblastoma trial (hr-nbl1). J. Clin. Oncol. 2021, 39, 3377–3390. 
210. Javanmardi, N.; Fransson, S.; Djos, A.; Umapathy, G.; Östensson, M.; Milosevic, J.; Borenäs, M.; Hallberg, B.; Kogner, P.; Mar-
tinsson, T.; et al. Analysis of alk, mycn, and the alk ligand alkal2 (fam150b/augalpha) in neuroblastoma patient samples with 
chromosome arm 2p rearrangements. GenesChromosomes Cancer 2019, 59, 50–57. 
211. Janoueix-Lerosey, I.; Schleiermacher, G.; Michels, E.; Mosseri, V.; Ribeiro, A.; Lequin, D.; Vermeulen, J.; Couturier, J.; Peuch-
maur, M.; Valent, A.; et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 2009, 27, 1026–
1033. 
212. Lastowska, M.; Viprey, V.; Santibanez-Koref, M.; Wappler, I.; Peters, H.; Cullinane, C.; Roberts, P.; Hall, A.G.; Tweddle, D.A.; 
Pearson, A.D.; et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and ex-
pression microarrays with survival data. Oncogene 2007, 26, 7432–7444. 
213. Vandesompele, J.; Baudis, M.; De Preter, K.; Van Roy, N.; Ambros, P.; Bown, N.; Brinkschmidt, C.; Christiansen, H.; Combaret, 
V.; Lastowska, M.; et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved 
outcome prediction in neuroblastoma. J. Clin. Oncol. 2005, 23, 2280–2299. 
214. Spitz, R.; Hero, B.; Ernestus, K.; Berthold, F. Fish analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups 
in neuroblastoma. Med. Pediatric Oncol. 2003, 41, 30–35. 
215. Chen, Q.R.; Bilke, S.; Wei, J.S.; Whiteford, C.C.; Cenacchi, N.; Krasnoselsky, A.L.; Greer, B.T.; Son, C.G.; Westermann, F.; 
Berthold, F.; et al. Cdna array-cgh profiling identifies genomic alterations specific to stage and mycn-amplification in neuro-
blastoma. BMC Genom. 2004, 5, 70. 
216. Zhang, R.; Fang, Y.F.; Wu, D.M.; Lin, Y.; Zhang, B.; Liu, M.K.; Bai, J.X.; Chen, F. Comparison of the efficacy of minimally invasive 
and open surgery on children with neuroblastoma: A meta-analysis. J. Laparoendosc. Adv. Surg. Tech. Part A 2021, 31, 829–838. 
217. Brisse, H.J.; McCarville, M.B.; Granata, C.; Krug, K.B.; Wootton-Gorges, S.L.; Kanegawa, K.; Giammarile, F.; Schmidt, M.; 
Shulkin, B.L.; Matthay, K.K.; et al. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the inter-
national neuroblastoma risk group project. Radiology 2011, 261, 243–257. 
218. Lu, X.; Pearson, A.; Lunec, J. The mycn oncoprotein as a drug development target. Cancer Lett. 2003, 197, 125–130. 
219. Kling, M.J.; Griggs, C.N.; McIntyre, E.M.; Alexander, G.; Ray, S.; Challagundla, K.B.; Joshi, S.S.; Coulter, D.W.; Chaturvedi, N.K. 
Synergistic efficacy of inhibiting mycn and mtor signaling against neuroblastoma. BMC Cancer 2021, 21, 1061. 
220. Di Giulio, S.; Colicchia, V.; Pastorino, F.; Pedretti, F.; Fabretti, F.; Nicolis di Robilant, V.; Ramponi, V.; Scafetta, G.; Moretti, M.; 
Licursi, V.; et al. A combination of parp and chk1 inhibitors efficiently antagonizes mycn-driven tumors. Oncogene 2021, 40, 1–
10. 
221. Yu, Y.; Ding, J.; Zhu, S.; Alptekin, A.; Dong, Z.; Yan, C.; Zha, Y.; Ding, H.F. Therapeutic targeting of both dihydroorotate dehy-
drogenase and nucleoside transport in mycn-amplified neuroblastoma. Cell Death Dis. 2021, 12, 821. 
222. Song, X.; Wang, L.; Wang, T.; Hu, J.; Wang, J.; Tu, R.; Su, H.; Jiang, J.; Qing, G.; Liu, H. Synergistic targeting of chk1 and mtor 
in myc-driven tumors. Carcinogenesis 2021, 42, 448–460. 
223. Waetzig, R.; Matthes, M.; Leister, J.; Penkivech, G.; Heise, T.; Corbacioglu, S.; Sommer, G. Comparing mtor inhibitor rapamycin 
with torin-2 within the rist molecular-targeted regimen in neuroblastoma cells. Int. J. Med Sci. 2021, 18, 137–149. 
224. Dedoni, S.; Marras, L.; Olianas, M.C.; Ingianni, A.; Onali, P. The neurotrophin receptor trkc as a novel molecular target of the 
antineuroblastoma action of valproic acid. Int. J. Mol. Sci. 2021, 22, 7790. 
225. Takatori, A.; Hossain, M.S.; Ogura, A.; Akter, J.; Nakamura, Y.; Nakagawara, A. Nlrr1 is a potential therapeutic target in neu-
roblastoma and mycn-driven malignant cancers. Front. Oncol. 2021, 11, 669667. 
226. Liu, C.; Gen, Y.; Tanimoto, K.; Muramatsu, T.; Inoue, J.; Inazawa, J. Concurrent targeting of map3k3 and brd4 by mir-3140-3p 
overcomes acquired resistance to bet inhibitors in neuroblastoma cells. Mol. Ther. Nucleic Acids 2021, 25, 83–92. 
227. Schultz, C.R.; Swanson, M.A.; Dowling, T.C.; Bachmann, A.S. Probenecid increases renal retention and antitumor activity of 
dfmo in neuroblastoma. Cancer Chemother. Pharmacol. 2021, 88, 607–617. 
Diseases 2021, 9, 78 39 of 39 
 
 
228. Dalton, K.M.; Krytska, K.; Lochmann, T.L.; Sano, R.; Casey, C.; D’Aulerio, A.; Khan, Q.A.; Crowther, G.S.; Coon, C.; Cai, J.; et 
al. Venetoclax-based rational combinations are effective in models of mycn-amplified neuroblastoma. Mol. Cancer Ther. 2021, 
20, 1400–1411. 
229. Ando, K.; Nakagawara, A. Acceleration or brakes: Which is rational for cell cycle-targeting neuroblastoma therapy? Biomolecules 
2021, 11, 750. 
230. Umapathy, G.; Mendoza-Garcia, P.; Hallberg, B.; Palmer, R.H. Targeting anaplastic lymphoma kinase in neuroblastoma. Acta 
Pathol. Microbiol. Immunol. Scand. 2019, 127, 288–302. 
231. Hu, Z.; Cheng, C.; Wang, Y.; Chen, T.; Tu, J.; Niu, C.; Xing, R.; Wang, Y.; Xu, Y. Synergistic effect of statins and abiraterone 
acetate on the growth inhibition of neuroblastoma via targeting androgen receptor. Front. Oncol. 2021, 11, 595285. 
232. Dubiella, C.; Pinch, B.J.; Koikawa, K.; Zaidman, D.; Poon, E.; Manz, T.D.; Nabet, B.; He, S.; Resnick, E.; Rogel, A.; et al. Sulfopin 
is a covalent inhibitor of pin1 that blocks myc-driven tumors in vivo. Nat. Chem. Biol. 2021, 17, 954–963. 
233. Wood, L.; Huang, M.; Zeki, J.; Gong, M.; Taylor, J.; Shimada, H.; Chiu, B. Combining inhibitors of brd4 and cyclin-dependent 
kinase can decrease tumor growth in neuroblastoma with mycn amplification. J. Pediatr. Surg. 2021, 56, 1199–1202. 
234. Dalton, K.M.; Lochmann, T.L.; Floros, K.V.; Calbert, M.L.; Kurupi, R.; Stein, G.T.; McClanaghan, J.; Murchie, E.; Egan, R.K.; 
Greninger, P.; et al. Catastrophic atp loss underlies a metabolic combination therapy tailored for mycn-amplified neuroblas-
toma. Proc. Natl. Acad. Sci. USA 2021, 118, e2009620118. 
235. Cheung, B.B.; Kleynhans, A.; Mittra, R.; Kim, P.Y.; Holien, J.K.; Nagy, Z.; Ciampa, O.C.; Seneviratne, J.A.; Mayoh, C.; Raipuria, 
M.; et al. A novel combination therapy targeting ubiquitin-specific protease 5 in mycn-driven neuroblastoma. Oncogene 2021, 
40, 2367–2381. 
 
